Comprehensive Addiction and Recovery Act of 2016

To authorize the Attorney General to award grants to address the national epidemics of prescription opioid abuse and heroin use. 1. Short title; table of contents (a) Short title This Act may be cited as the Comprehensive Addiction and Recovery Act of 2015 (b) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title; table of contents. Sec. 2. Findings. Sec. 3. Definitions. TITLE I—Prevention and education Sec. 101. Development of best prescribing practices. Sec. 102. National education campaign. Sec. 103. Community-based coalition enhancement grants to address local drug crises. TITLE II—Law enforcement and treatment Sec. 201. Treatment alternative to incarceration programs. Sec. 202. Law enforcement naloxone training and implementation demonstration. Sec. 203. Prescription drug take back expansion. TITLE III—Treatment and recovery Sec. 301. Evidence-based opioid and heroin treatment and interventions demonstration. Sec. 302. Criminal justice medication assisted treatment and interventions demonstration. Sec. 303. National youth recovery initiative. Sec. 304. Building communities of recovery. TITLE IV—Addressing collateral consequences Sec. 401. Correctional education demonstration grant program. Sec. 402. Revision of FAFSA form. Sec. 403. National Task Force on Recovery and Collateral Consequences. TITLE V—Addiction and treatment services for women, families, and veterans Sec. 501. Authority to award competitive grants to address opioid and heroin abuse by pregnant and parenting female offenders. Sec. 502. Grants for family-based substance abuse treatment. Sec. 503. Veterans’ treatment courts. TITLE VI—Incentivizing State comprehensive initiatives to address opioid and heroin abuse Sec. 601. State demonstration grants for comprehensive opioid abuse response. TITLE VII—Offset; GAO report Sec. 701. Offset. Sec. 702. GAO report on IMD exclusion. 2. Findings Congress finds the following: (1) The abuse of heroin and prescription painkillers is having a devastating effect on public health and safety in communities across the United States. According to the Centers for Disease Control and Prevention, drug overdose deaths now surpass traffic crashes in the number of deaths caused by injury in the United States. In 2011, an average of about 110 people in the United States died from drug overdose every day. (2) Law enforcement officials and treatment experts throughout the country report that many prescription opioid users have turned to heroin as a cheaper or more easily obtained alternative to prescription drugs. (3) Opioid pain relievers are the most widely misused or abused controlled prescription drugs (commonly referred to as CPDs DAWN (4) According to a report by the National Association of State Alcohol and Drug Abuse Directors (commonly referred to as NASADAD (5) Substance use disorders are a treatable disease. Discoveries in the science of addiction have led to advances in the treatment of substance use disorders that help people stop abusing drugs and prescription medications and resume their productive lives. (6) According to the National Survey on Drug Use and Health, approximately 22,700,000 people in the United States needed substance use disorder treatment in 2013, but only 2,500,000 people received it. Furthermore, current treatment services are not adequate to meet demand. According to a report commissioned by SAMHSA, there are approximately 32 providers for every 1,000 individuals needing substance use disorder treatment. In some States, the ratio is much lower. (7) Effective substance abuse prevention can yield major economic dividends. (8) According to the National Institute on Drug Abuse, when schools and communities properly implement science-validated substance abuse prevention programs, abuse of alcohol, tobacco, and illicit drugs is reduced. Such programs help teachers, parents, and healthcare professionals shape the perceptions of youths about the risks of drug abuse. (9) Diverting individuals with substance use disorders from criminal justice systems into community-based treatment can save billions of dollars and prevent sizeable numbers of crimes, arrests, and re-incarcerations over the course of those individuals’ lives. (10) According to the Drug Enforcement Agency, more than 1,700 tons of expired, unwanted prescription medications have been collected during the past 3 1/2 Public Law 111–273 (11) Research shows that combining treatment medications with behavioral therapy is the best way to facilitate success for most patients. Treatment approaches must be tailored to address the drug abuse patterns and drug-related medical, psychiatric, and social problems of each individual. Different types of medications may be useful at different stages of treatment or recovery to help a patient stop using drugs, stay in treatment, and avoid relapse. (12) Research indicates that combating the opioid crisis, including abuse of prescription painkillers and, increasingly, heroin, requires a multi-pronged approach that involves reducing drug diversion, expanding delivery of existing treatments (including medication assisted treatments), expanding access to overdose medications and interventions, and the development of new medications for pain that can augment the existing treatment arsenal. (13) Individuals with mental illness, especially severe mental illness, are at considerably higher risk for substance abuse than the general population, and the presence of a mental illness complicates recovery from substance abuse. 3. Definitions In this Act— (1) the term medication assisted treatment (2) the term ONDCP Recovery Branch (3) the term opioid (4) the term State I Prevention and education 101. Development of best prescribing practices (a) Inter-Agency task force Not later than 120 days after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary task force (b) Membership The task force shall be comprised of— (1) representatives of— (A) the Department of Health and Human Services; (B) the Department of Veterans Affairs; (C) the Department of Defense; (D) the Drug Enforcement Administration; (E) the Centers for Disease Control and Prevention; (F) the Institute of Medicine; and (G) the Office of National Drug Control Policy; (2) the Director of the National Institutes of Health; (3) physicians, dentists, and non-physician prescribers; (4) pharmacists; (5) experts in the fields of pain research and addiction research; (6) representatives of— (A) pain management professional organizations; (B) the mental health treatment community; (C) the addiction treatment community; (D) pain advocacy groups; and (E) groups with expertise around overdose reversal; and (7) other stakeholders, as the Secretary determines appropriate. (c) Duties The task force shall— (1) not later than 180 days after the date on which the task force is convened under subsection (a), develop best practices for pain management (including chronic and acute pain) and prescribing pain medication, taking into consideration— (A) existing pain management research; (B) recommendations from relevant conferences; (C) ongoing efforts at the State and local levels and by medical professional organizations to develop improved pain management strategies; and (D) the management of high-risk populations, other than populations who suffer pain, who— (i) may use or be prescribed benzodiazepines, alcohol, and diverted opioids; or (ii) receive opioids in the course of medical care; (2) solicit and take into consideration public comment on the practices developed under paragraph (1), amending such best practices if appropriate; and (3) develop a strategy for disseminating information about the best practices developed under paragraphs (1) and (2) to prescribers, health professionals, pharmacists, State medical boards, and other parties, as the Secretary determines appropriate. (d) Limitation The task force shall not have rulemaking authority. (e) Report Not later than 270 days after the date on which the task force is convened under subsection (a), the task force shall submit to Congress a report that includes— (1) the strategy for disseminating best practices developed under subsection (c); (2) the results of a feasibility study on linking best practices developed under subsection (c) to receiving and renewing registrations under section 303(f) of the Controlled Substances Act ( 21 U.S.C. 823(f) (3) recommendations on how to apply best practices developed under subsection (c) to improve prescribing practices at medical facilities, including medical facilities of the Veterans Health Administration. 102. National education campaign Title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3711 et seq. MM Drug treatment grants 3031. Definitions In this part— (1) the term civil liability protection law (2) the term medication assisted treatment (3) the term opioid (4) the term Single State Authority for Substance Abuse 42 U.S.C. 17521(e) 3032. National education campaign (a) Definitions In this section— (1) the term eligible entity (2) the terms elementary school secondary school 20 U.S.C. 7801 (b) Program authorized The Attorney General, in coordination with the Secretary of Health and Human Services, the Director of the Office of National Drug Control Policy, the Secretary of Education, the Administrator of the Substance Abuse and Mental Health Services Administration, and the Director of the Centers for Disease Control and Prevention, may make grants to eligible entities to expand educational efforts to prevent abuse of opioids, heroin, and other substances of abuse, understand addiction as a chronic disease, and promote treatment and recovery, including— (1) parent and caretaker-focused prevention efforts, including— (A) the development of research-based community education online and social media materials with an accompanying toolkit that can be disseminated to communities to educate parents and other caretakers of teens on— (i) how to educate teens about opioid and heroin abuse; (ii) how to intervene if a parent thinks or knows their teen is abusing opioids or heroin; (iii) signs of opioid or heroin overdose; and (iv) the use of naloxone to prevent death from opioid or heroin overdose; (B) the development of detailed digital and print educational materials to accompany the online and social media materials and toolkit described in subparagraph (A); (C) the development and dissemination of public service announcements to— (i) raise awareness of heroin and opioid abuse among parents and other caretakers; (ii) motivate parents and other caretakers to visit online educational materials on heroin and opioid abuse; and (iii) provide information for public health agencies and nonprofit organizations that provide overdose reversal and prevention services and community referrals; and (D) the dissemination of educational materials to the media through— (i) a town hall or panel discussion with experts; (ii) a press release; (iii) an online news release; (iv) a media tour; and (v) sharable infographics; (2) prevention efforts focused on teenagers, young adults, and college students, including the development of— (A) a national digital campaign; (B) a community education toolkit for use by community coalitions; (C) evidence-based resources for prevention and treatment professionals targeting individuals who are between 18 and 24 years of age, including college students; and (D) technical support centers for prevention and treatment professionals, elementary and secondary school-based professionals, and college-based professionals, including recovery staff, to implement and sustain evidence-based educational and prevention programs; (3) campaigns to inform individuals about available resources to aid in recovery from substance use disorder; (4) encouragement of individuals in or seeking recovery from substance use disorder to enter the health care system; or (5) adult-focused awareness efforts, including efforts focused on older adults, relating to prescription medication disposal, opioid and heroin abuse, signs of overdose, and the use of naloxone for reversal. (c) Application (1) In general An eligible entity desiring a grant under this section shall submit an application to the Attorney General— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Attorney General may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) describe the evidence-based methodology and outcome measurements that will be used to evaluate the program funded with a grant under this section; (B) specifically explain how the measurements described in subparagraph (A) will provide valid measures of the impact of the program described in subparagraph (A); (C) describe how the program described in subparagraph (A) could be broadly replicated if demonstrated to be effective; (D) demonstrate that all planned services will be research-informed, which may include evidence-based practices documented in— (i) the report of the Institute of Medicine entitled Preventing Mental, Emotional, and Behavioral Disorders Among Young People (ii) the National Registry of Effective Programs and Practices (commonly referred to as NREPP (E) demonstrate that the eligible entity will effectively integrate and sustain the program described in subparagraph (A) into curriculum or community outreach efforts. (d) Use of funds A grantee shall use a grant received under this section for expenses of educational efforts to— (1) prevent abuse of opioids, heroin, alcohol, and other drugs; or (2) promote treatment and recovery. (e) Duration The Attorney General shall award grants under this section for a period not to exceed 2 years. (f) Priority consideration with respect to States In awarding grants to States under this section, the Attorney General shall give priority to a State that provides civil liability protection for first responders, health professionals, and family members administering naloxone to counteract opioid overdoses by— (1) enacting legislation that provides such civil liability protection; or (2) providing a certification by the attorney general of the State that the attorney general has— (A) reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders, health care professionals, family members, and other individuals who may administer naloxone to individuals reasonably believed to be suffering from opioid overdose; and (B) concluded that the law described in subparagraph (A) provides adequate civil liability protection applicable to such persons. (g) Information sharing The Office of the Attorney General, in coordination with the Substance Abuse and Mental Health Services Administration and the Department of Education, shall review existing evidence-based programs and emerging practices and programs and provide information to schools and communities about such programs and practices. (h) Authorization of appropriations There are authorized to be appropriated to carry out this section $2,500,000 for each of fiscal years 2016 through 2020. . 103. Community-based coalition enhancement grants to address local drug crises Part MM of title I of the Omnibus Crime Control and Safe Streets Act of 1968, as added by section 102, is amended by adding at the end the following: 3033. Community-based coalition enhancement grants to address local drug crises (a) Definitions In this section— (1) the term Drug-Free Communities Act of 1997 21 U.S.C. 1521 et seq. (2) the term eligible entity (A) on or before the date of submitting an application for a grant under this section, receives or has received a grant under the Drug-Free Communities Act of 1997; and (B) has documented, using local data, rates of abuse of opioids at levels that are— (i) significantly higher than the national average as determined by the Attorney General (including appropriate consideration of the Monitoring the Future Survey published by the National Institute on Drug Abuse and the National Survey on Drug Use and Health by the Substance Abuse and Mental Health Service Administration); or (ii) higher than the national average, as determined by the Attorney General (including appropriate consideration of the surveys described in clause (i)), over a sustained period of time; and (3) the term local drug crisis (A) a sudden increase in the abuse of opioids, as documented by local data; or (B) the abuse of prescription medications, specifically opioids, that is significantly higher than the national average, over a sustained period of time, as documented by local data. (b) Program authorized The Attorney General, in coordination with the Director, may make grants to eligible entities to implement comprehensive community-wide strategies that address local drug crises within the area served by the eligible entity. (c) Application (1) In general An eligible entity desiring a grant under this section shall submit an application to the Attorney General at such time, in such manner, and accompanied by such information as the Attorney General may require. (2) Criteria As part of an application for a grant under this section, the Attorney General shall require an eligible entity to submit a detailed, comprehensive, multi-sector plan for addressing the local drug crisis within the area served by the eligible entity. (d) Use of funds An eligible entity shall use a grant received under this section— (1) for programs designed to implement comprehensive community-wide prevention strategies to address local drug crisis in the area served by the eligible entity, in accordance with the plan submitted under subsection (c)(2); and (2) to obtain specialized training and technical assistance from the organization funded under section 4 of Public Law 107–82 21 U.S.C. 1521 (e) Grant amounts and duration (1) Amounts The Attorney General may not award a grant under this section for a fiscal year in an amount that exceeds— (A) the amount of non-Federal funds raised by the eligible entity, including in-kind contributions, for that fiscal year; or (B) $75,000. (2) Duration The Attorney General shall award grants under this section for a period not to exceed 4 years. (f) Supplement not supplant An eligible entity shall use Federal funds received under this section only to supplement the funds that would, in the absence of those Federal funds, be made available from other Federal and non-Federal sources for the activities described in this section, and not to supplant those funds. (g) Evaluation A grant under this section shall be subject to the same evaluation requirements and procedures as the evaluation requirements and procedures imposed on the recipient of a grant under the Drug-Free Communities Act of 1997. (h) Limitation on administrative expenses Not more than 8 percent of the amounts made available pursuant to subsection (i) for a fiscal year may be used by the Attorney General to pay for administrative expenses. (i) Authorization of appropriations There are authorized to be appropriated to carry out this section $5,000,000 for each of fiscal years 2016 through 2020. . II Law enforcement and treatment 201. Treatment alternative to incarceration programs Part MM of the Omnibus Crime Control and Safe Streets Act of 1968, as amended by section 103, is amended by adding at the end the following: 3034. Treatment alternative to incarceration programs (a) Definitions In this section— (1) the term eligible entity (2) the term eligible participant (A) comes into contact with the juvenile justice system or criminal justice system or is arrested or charged with an offense; (B) has a history of or a current— (i) substance use disorder; (ii) mental illness; or (iii) co-occurring mental illness and substance use disorders; and (C) has been approved for participation in a program funded under this section by, as applicable depending on the stage of the criminal justice process, the relevant law enforcement agency or prosecuting attorney, defense attorney, probation or corrections official, judge, or representative from the relevant mental health or substance abuse agency. (b) Program authorized The Attorney General may make grants to eligible entities to develop, implement, or expand a treatment alternative to incarceration program for eligible participants, including— (1) pre-booking treatment alternative to incarceration programs, including— (A) law enforcement training on substance use disorders, mental illness, and co-occurring mental illness and substance use disorders; (B) receiving centers as alternatives to incarceration of eligible participants; (C) specialized response units for calls related to substance use disorders, mental illness, and co-occurring mental illness and substance use disorders; and (D) other arrest and pre-booking treatment alternative to incarceration models; and (2) post-booking treatment alternative to incarceration programs, including— (A) specialized clinical case management; (B) pre-trial services related to substances use disorders, mental illness, and co-occurring mental illness and substance use disorders; (C) prosecutor and defender based programs; (D) specialized probation; (E) programs utilizing the American Society of Addiction Medicine patient placement criteria; (F) treatment and rehabilitation programs and recovery support services; and (G) drug courts, DWI courts, and veterans treatment courts. (c) Application (1) In general An eligible entity desiring a grant under this section shall submit an application to the Attorney General— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Attorney General may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) provide extensive evidence of collaboration with State and local government agencies overseeing health, community corrections, courts, prosecution, substance abuse, mental health, victims services, and employment services, and with local law enforcement agencies; (B) demonstrate consultation with the Single State Authority for Substance Abuse; (C) demonstrate that evidence-based treatment practices will be utilized; and (D) demonstrate that evidenced-based screening and assessment tools will be utilized to place participants in the treatment alternative to incarceration program. (d) Requirements Each eligible entity awarded a grant for a treatment alternative to incarceration program under this section shall— (1) determine the terms and conditions of participation in the program by eligible participants, taking into consideration the collateral consequences of an arrest, prosecution, or criminal conviction; (2) ensure that each substance abuse and mental health treatment component is licensed and qualified by the relevant jurisdiction; (3) for programs described in subsection (b)(2), organize an enforcement unit comprised of appropriately trained law enforcement professionals under the supervision of the State, tribal, or local criminal justice agency involved, the duties of which shall include— (A) the verification of addresses and other contacts of each eligible participant who participates or desires to participate in the program; and (B) if necessary, the location, apprehension, arrest, and return to court of an eligible participant in the program who has absconded from the facility of a treatment provider or has otherwise violated the terms and conditions of the program, consistent with Federal and State confidentiality requirements; (4) notify the relevant criminal justice entity if any eligible participant in the program absconds from the facility of the treatment provider or otherwise violates the terms and conditions of the program, consistent with Federal and State confidentiality requirements; (5) submit periodic reports on the progress of treatment or other measured outcomes from participation in the program of each eligible offender participating in the program to the relevant State, tribal, or local criminal justice agency; (6) describe the evidence-based methodology and outcome measurements that will be used to evaluate the program, and specifically explain how such measurements will provide valid measures of the impact of the program; and (7) describe how the program could be broadly replicated if demonstrated to be effective. (e) Use of funds An eligible entity shall use a grant received under this section for expenses of a treatment alternative to incarceration program, including— (1) salaries, personnel costs, equipment costs, and other costs directly related to the operation of the program, including the enforcement unit; (2) payments for treatment providers that are approved by the relevant State or tribal jurisdiction and licensed, if necessary, to provide needed treatment to eligible offenders participating in the program, including medication assisted treatment, aftercare supervision, vocational training, education, and job placement; and (3) payments to public and nonprofit private entities that are approved by the State or tribal jurisdiction and licensed, if necessary, to provide alcohol and drug addiction treatment and mental health treatment to eligible offenders participating in the program. (f) Supplement not supplant An eligible entity shall use Federal funds received under this section only to supplement the funds that would, in the absence of those Federal funds, be made available from other Federal and non-Federal sources for the activities described in this section, and not to supplant those funds. (g) Geographic distribution The Attorney General shall ensure that, to the extent practicable, the geographical distribution of grants under this section is equitable and includes a grant to an eligible entity in— (1) each State; (2) rural, suburban, and urban areas; and (3) tribal jurisdictions. (h) Priority consideration with respect to States In awarding grants to States under this section, the Attorney General shall give priority to a State that provides civil liability protection for first responders, health professionals, and family members administering naloxone to counteract opioid overdoses by— (1) enacting legislation that provides such civil liability protection; or (2) providing a certification by the attorney general of the State that the attorney general has— (A) reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders, health care professionals, family members, and other individuals who may administer naloxone to individuals reasonably believed to be suffering from opioid overdose; and (B) concluded that the law described in subparagraph (A) provides adequate civil liability protection applicable to such persons. (i) Reports and evaluations (1) In general Each fiscal year, each recipient of a grant under this section during that fiscal year shall submit to the Attorney General a report on the outcomes of activities carried out using that grant in such form, containing such information, and on such dates as the Attorney General shall specify. (2) Contents A report submitted under paragraph (1) shall— (A) describe best practices for treatment alternatives; and (B) identify training requirements for law enforcement officers who participate in treatment alternative to incarceration programs. (j) Authorization of appropriations There are authorized to be appropriated to carry out this section $5,000,000 for each of fiscal years 2016 through 2020. . 202. Law enforcement naloxone training and implementation demonstration Part MM of the Omnibus Crime Control and Safe Streets Act of 1968, as amended by section 201, is amended by adding at the end the following: 3035. Law enforcement naloxone training and implementation demonstration (a) Definition In this section, the term eligible entity (b) Program authorized The Attorney General, in coordination with the Secretary of Health and Human Services and the Director of the Office of National Drug Control Policy, may make grants to eligible entities to create a demonstration law enforcement program to prevent opioid and heroin overdose death. (c) Application (1) In general An eligible entity desiring a grant under this section shall submit an application to the Attorney General— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Attorney General may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) describe the evidence-based methodology and outcome measurements that will be used to evaluate the program funded with a grant under this section, and specifically explain how such measurements will provide valid measures of the impact of the program; (B) describe how the program could be broadly replicated if demonstrated to be effective; (C) identify the governmental and community agencies that the program will coordinate; and (D) describe how law enforcement agencies will coordinate with their corresponding State substance abuse and mental health agencies to identify protocols and resources that are available to victims and families, including information on treatment and recovery resources. (d) Use of funds An eligible entity shall use a grant received under this section to— (1) make naloxone available to be carried and administered by law enforcement officers; (2) train and provide resources for law enforcement officers on carrying and administering naloxone for the prevention of opioid and heroin overdose death; and (3) establish processes, protocols, and mechanisms for referral to treatment. (e) Grant amounts and duration (1) Maximum amount The Attorney General may not award a grant under this section in an amount that exceeds $500,000. (2) Duration The Attorney General shall award grants under this section for a period not to exceed 2 years. (f) Technical assistance grants The Attorney General shall make a grant for the purpose of providing technical assistance and training on the use of naloxone to reverse overdose deaths and mechanisms for referral to treatment for an eligible entity receiving a grant under this section. (g) Evaluation The Attorney General shall conduct an evaluation of grants made under this section to determine— (1) the number of officers equipped with naloxone for the prevention of fatal opioid and heroin overdose; (2) the number of opioid and heroin overdoses reversed by officers receiving training and supplies of naloxone through a grant received under this section; (3) the number of calls for service related to opioid and heroin overdose; (4) the extent to which overdose victims and families receive information about treatment services and available data describing treatment admissions; and (5) the research, training, and naloxone supply needs of law enforcement and first responder agencies, including those agencies that are not receiving grants under this section. (h) Authorization of appropriations There are authorized to be appropriated to carry out this section $5,000,000 for each of fiscal years 2016 through 2020. . 203. Prescription drug take back expansion Part MM of the Omnibus Crime Control and Safe Streets Act of 1968, as amended by section 202, is amended by adding at the end the following: 3036. Prescription drug take back expansion (a) Definition In this section, the term eligible entity (1) a State, local, or tribal law enforcement agency; (2) a manufacturer, distributor, or reverse distributor of prescription medications; (3) a retail pharmacy; (4) a registered narcotic treatment program; (5) a hospital or clinic with an on-site pharmacy; (6) an eligible long-term care facility; or (7) any other entity authorized by the Drug Enforcement Administration to dispose of prescription medications. (b) Program authorized The Attorney General, in coordination with the Administrator of the Drug Enforcement Administration, the Secretary of Health and Human Services, and the Director of the Office of National Drug Control Policy, may make grants to eligible entities to expand or make available disposal sites for unwanted prescription medications. (c) Application (1) In general An eligible entity desiring a grant under this section shall submit an application to the Attorney General— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Attorney General may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) describe the evidence-based methodology and outcome measurements that will be used to evaluate the program funded with a grant under this section, and specifically explain how such measurements will provide valid measures of the impact of the program; (B) describe how the program could be broadly replicated if demonstrated to be effective; and (C) identify the governmental and community agencies that will coordinate the program. (d) Use of funds An eligible entity shall use a grant received under this section for— (1) expenses of a prescription drug disposal site, including materials and resources; (2) implementing disposal procedures and processes; (3) implementing community education strategies, including community education materials and resources; (4) replicating a prescription drug take back initiative throughout multiple jurisdictions; and (5) training of law enforcement officers and other community participants. (e) Grant amounts and duration (1) Maximum amount The Attorney General may not award a grant under this section in an amount that exceeds $250,000. (2) Duration The Attorney General shall award grants under this section for a period not to exceed 2 years. (f) Technical assistance grant The Attorney General shall make a grant to a national nonprofit organization to provide technical assistance and training for an eligible entity receiving a grant under this section. (g) Evaluation (1) In general The Attorney General shall make a grant for evaluation of the performance of each eligible entity receiving a grant under this section. (2) Reports Each fiscal year, the recipient of a grant under this subsection shall submit to the Attorney General a report that evaluates— (A) the effectiveness of the prescription drug take back program of each eligible entity receiving a grant under this section; and (B) the effect of disposal efforts on drug circulation. (h) Authorization of appropriations There are authorized to be appropriated to carry out this section $2,500,000 for each of fiscal years 2016 through 2020. . III Treatment and recovery 301. Evidence-based opioid and heroin treatment and interventions demonstration Subpart 1 of part B of title V of the Public Health Service Act ( 42 U.S.C. 290bb et seq. (1) by redesignating section 514 ( 42 U.S.C. 290bb–9 Public Law 106–310 (2) by adding at the end the following: 514C. Evidence-based opioid and heroin treatment and interventions demonstration (a) Grants (1) Authority to make grants The Director of the Center for Substance Abuse Treatment (referred to in this section as the Director 25 U.S.C. 1603 (2) Recipients The entities receiving grants under paragraph (1) shall be selected by the Director. (3) Nature of activities The grant funds awarded under paragraph (1) shall be used for activities that are based on reliable scientific evidence of efficacy in the treatment of problems related to heroin or other opioids. (b) Geographic distribution The Director shall ensure that grants awarded under subsection (a) are distributed equitably among the various regions of the Nation and among rural, urban, and suburban areas that are affected by the use of heroin or other opioids. (c) Additional activities The Director shall— (1) evaluate the activities supported by grants awarded under subsection (a); (2) disseminate widely such significant information derived from the evaluation as the Director considers appropriate; (3) provide States, Indian tribes and tribal organizations, and providers with technical assistance in connection with the provision of treatment of problems related to heroin and other opioids; and (4) fund only those applications that specifically support recovery services as a critical component of the grant program. (d) Definition The term medication assisted treatment (e) Authorization of appropriations (1) In general There are authorized to be appropriated to carry out this section $12,000,000 for fiscal year 2016 and such sums as may be necessary for each of fiscal years 2016 through 2020. (2) Use of certain funds Of the funds appropriated to carry out this section in any fiscal year, the lesser of 5 percent of such funds or $1,000,000 shall be available to the Director for purposes of carrying out subsection (c). . 302. Criminal justice medication assisted treatment and interventions demonstration Part MM of the Omnibus Crime Control and Safe Streets Act of 1968, as amended by section 203, is amended by adding at the end the following: 3037. Criminal justice medication assisted treatment and interventions demonstration (a) Definitions In this section— (1) the term criminal justice agency (A) court; (B) prison; (C) jail; or (D) other agency that performs the administration of criminal justice, including prosecution, pretrial services, and community supervision; and (2) the term eligible entity (b) Program authorized The Attorney General, in coordination with the Secretary of Health and Human Services and the Director of the Office of National Drug Control Policy, may make grants to eligible entities to implement medication assisted treatment programs through criminal justice agencies. (c) Application (1) In general An eligible entity desiring a grant under this section shall submit an application to the Attorney General— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Attorney General may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) certify that each medication assisted treatment program funded with a grant under this section has been developed in consultation with the Single State Authority for Substance Abuse; and (B) describe how data will be collected and analyzed to determine the effectiveness of the program described in subparagraph (A). (d) Use of funds An eligible entity shall use a grant received under this section for expenses of— (1) a medication assisted treatment program, including the expenses of prescribing medications recognized by the Food and Drug Administration for opioid treatment in conjunction with psychological and behavioral therapy; (2) training criminal justice agency personnel and treatment providers on medication assisted treatment; (3) cross-training personnel providing behavioral health and health services, administration of medicines, and other administrative expenses, including required reports; and (4) the provision of recovery coaches who are responsible for providing mentorship and transition plans to individuals reentering society following incarceration or alternatives to incarceration. (e) Grant amounts and duration (1) Maximum amount The Attorney General may not award a grant under this section in an amount that exceeds $750,000. (2) Duration The Attorney General shall award grants under this section for a period not to exceed 2 years. (f) Priority consideration with respect to States In awarding grants to States under this section, the Attorney General shall give priority to a State that provides civil liability protection for first responders, health professionals, and family members administering naloxone to counteract opioid overdoses by— (1) enacting legislation that provides such civil liability protection; or (2) providing a certification by the attorney general of the State that the attorney general has— (A) reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders, health care professionals, family members, and other individuals who may administer naloxone to individuals reasonably believed to be suffering from opioid overdose; and (B) concluded that the law described in subparagraph (A) provides adequate civil liability protection applicable to such persons. (g) Technical assistance The Attorney General, in coordination with the Director of the National Institute on Drug Abuse and the Secretary of Health and Human Services, shall provide technical assistance and training for an eligible entity receiving a grant under this section. (h) Reports (1) In general An eligible entity receiving a grant under this subsection shall submit a report to the Attorney General on the outcomes of each grant received under this section for individuals receiving medication assisted treatment, based on— (A) the recidivism of the individuals; (B) the treatment outcomes of the individuals, including maintaining abstinence from illegal, unauthorized, and unprescribed or undispensed opioids and heroin; (C) a comparison of the cost of providing medication assisted treatment to the cost of incarceration or other participation in the criminal justice system; (D) the housing status of the individuals; and (E) the employment status of the individuals. (2) Contents and timing Each report described in paragraph (1) shall be submitted annually in such form, containing such information, and on such dates as the Attorney General shall specify. (i) Authorization of appropriations There are authorized to be appropriated to carry out this section $5,000,000 for each of fiscal years 2016 through 2020. . 303. National youth recovery initiative (a) Definitions In this section: (1) Eligible entity The term eligible entity (A) a high school that has been accredited as a recovery high school by the Association of Recovery Schools; (B) an accredited high school that is seeking to establish or expand recovery support services; (C) an institution of higher education; (D) a recovery program at a nonprofit collegiate institution; or (E) a nonprofit organization. (2) Institution of higher education The term institution of higher education 20 U.S.C. 1001 (3) Recovery program The term recovery program (A) means a program to help individuals who are recovering from substance use disorders to initiate, stabilize, and maintain healthy and productive lives in the community; and (B) includes peer-to-peer support and communal activities to build recovery skills and supportive social networks. (b) Grants authorized The ONDCP Recovery Branch, in consultation with the Secretary of Education, may award grants to eligible entities to enable the entities to— (1) provide substance use recovery support services to young people in high school and enrolled in institutions of higher education; (2) help build communities of support for young people in recovery through a spectrum of activities such as counseling and healthy and wellness-oriented social activities; and (3) encourage initiatives designed to help young people achieve and sustain recovery from substance use disorders. (c) Use of funds Grants awarded under subsection (b) may be used for activities to develop, support, and maintain youth recovery support services, including— (1) the development and maintenance of a dedicated physical space for recovery programs; (2) dedicated staff for the provision of recovery programs; (3) healthy and wellness-oriented social activities and community engagement; (4) establishment of recovery high schools; (5) coordination of recovery programs with— (A) substance use disorder treatment programs and systems; (B) providers of mental health services; (C) primary care providers; (D) the criminal justice system, including the juvenile justice system; (E) employers; (F) housing services; (G) child welfare services; (H) institutions of secondary higher education and institutions of higher education; and (I) other programs or services related to the welfare of an individual in recovery from a substance use disorder; (6) the development of peer-to-peer support programs or services; and (7) additional activities that help youths and young adults to achieve recovery from substance use disorders. (d) Resource center The ONDCP Recovery Branch shall establish a resource center to provide technical support to recipients of grants under this section. (e) Authorization of appropriations There are authorized to be appropriated to carry out this section $3,000,000 for fiscal year 2016 and each of the 5 succeeding fiscal years. 304. Building communities of recovery (a) Definition In this section, the term recovery community organization (1) mobilizes resources within and outside of the recovery community to increase the prevalence and quality of long-term recovery from substance use disorders; and (2) is wholly or principally governed by people in recovery for substance use disorders who reflect the community served. (b) Grants authorized The ONDCP Recovery Branch, in consultation with the Substance Abuse and Mental Health Services Administration, may award grants to recovery community organizations to enable such organizations to develop, expand, and enhance recovery services. (c) Maximum grant amount The ONDCP Recovery Branch may not award a grant under this section in an amount that exceeds $200,000. (d) Federal share The Federal share of the costs of a program funded by a grant under this section may not exceed 50 percent. (e) Use of funds Grants awarded under subsection (b)— (1) shall be used to develop, expand, and enhance community and statewide recovery support services; and (2) may be used to— (A) advocate for individuals in recovery from substance use disorders; (B) build connections between recovery networks, between recovery community organizations, and with other recovery support services, including— (i) substance use disorder treatment programs and systems; (ii) providers of mental health services; (iii) primary care providers; (iv) the criminal justice system; (v) employers; (vi) housing services; (vii) child welfare agencies; and (viii) other recovery support services that facilitate recovery from substance use disorders; (C) reduce the stigma associated with substance use disorders; (D) conduct public education and outreach on issues relating to substance use disorders and recovery, including— (i) how to identify the signs of addiction; (ii) the resources that are available for individuals struggling with addiction; (iii) the resources that are available to help support individuals in recovery; and (iv) information on the medical consequences of substance use disorders, including neonatal abstinence syndrome and potential infection with human immunodeficiency virus and viral hepatitis; and (E) carry out other activities that strengthen the network of community support for individuals in recovery. (f) Resource center The ONDCP Recovery Branch shall establish a resource center to provide technical assistance to recipients of grants under this section and to provide information to individuals seeking to support people in recovery from substance use disorders. (g) Authorization of appropriations There are authorized to be appropriated to carry out this section $5,700,000 in fiscal year 2016 and each of the 3 succeeding fiscal years. IV Addressing collateral consequences 401. Correctional education demonstration grant program Title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3711 et seq. (1) by redesignating part KK as part LL; (2) by redesignating sections 3011 and 3012 as sections 3021 and 3022, respectively; and (3) by inserting before part LL, as redesignated, the following: KK Correctional education demonstration grant program 3011. Correctional education demonstration grant program (a) Definition In this section, the term eligible entity (b) Grant program authorized The Attorney General may make grants of not more than $750,000 to eligible entities to design, implement, and expand educational programs for offenders in prisons, jails, and juvenile facilities, including to pay for— (1) basic education, secondary level academic education, high school equivalency examination preparation, career technical education, and English as a second language instruction at the basic, secondary, or post-secondary levels, for adult and juvenile populations; (2) screening and assessment of inmates to assess education level, needs, occupational interest or aptitude, risk level, and other needs, and case management services; (3) hiring and training of instructors and aides, reimbursement of non-corrections staff and experts, reimbursement of stipends paid to inmate tutors or aides, and the costs of training inmate tutors and aides; (4) instructional supplies and equipment, including occupational program supplies and equipment to the extent that the supplies and equipment are used for instructional purposes; (5) partnerships and agreements with community colleges, universities, and career technology education program providers, including tuition payments; (6) certification programs providing recognized high school equivalency certificates and industry recognized credentials; and (7) technology solutions to— (A) meet the instructional, assessment, and information needs of correctional populations; and (B) facilitate the continued participation of incarcerated students in community-based education programs after the students are released from incarceration. (c) Application An eligible entity desiring a grant under this section shall submit to the Attorney General an application in such form and manner, at such time, and accompanied by such information as the Attorney General specifies. (d) Priority considerations In awarding grants under this section, the Attorney General shall give priority to applicants that— (1) assess the level of risk and need of inmates, including by— (A) assessing the need for English as a second language instruction; (B) conducting educational assessments; and (C) assessing occupational interests and aptitudes; (2) target educational services to assessed needs, including academic and occupational at the basic, secondary, or post-secondary level; (3) target career technology education programs to— (A) areas of identified occupational demand; and (B) employment opportunities in the communities in which students are reasonably expected to reside post-release; (4) include a range of appropriate educational opportunities at the basic, secondary, and post-secondary levels; (5) include opportunities for students to attain industry recognized credentials; (6) include partnership or articulation agreements linking institutional education programs with community sited programs provided by adult education program providers and accredited institutions of higher education, community colleges, and vocational training institutions; and (7) explicitly include career pathways models offering opportunities for incarcerated students to develop academic skills, in-demand occupational skills and credentials, occupational experience in institutional work programs or work release programs, and linkages with employers in the community, so that incarcerated students have opportunities to embark on careers with strong prospects for both post-release employment and advancement in a career ladder over time. (e) Requirements An eligible entity desiring a grant under this section shall— (1) describe the evidence-based methodology and outcome measurements that will be used to evaluate each program funded with a grant under this section, and specifically explain how such measurements will provide valid measures of the impact of the program; and (2) describe how the program described in paragraph (1) could be broadly replicated if demonstrated to be effective. (f) Control of internet access An entity that receives a grant under this section shall restrict access to the Internet by prisoners, as appropriate, to ensure public safety. 3012. Authorization of appropriations There are authorized to be appropriated $5,000,000 to carry out this part for fiscal years 2016 through 2020. . 402. Revision of FAFSA form Section 483 of the Higher Education Act of 1965 ( 20 U.S.C. 1090 (i) Convictions The Secretary shall not include any question about the conviction of an applicant for the possession or sale of illegal drugs on the FAFSA (or any other form developed under subsection (a)). . 403. National Task Force on Recovery and Collateral Consequences (a) Definition In this section, the term collateral consequence (1) imposed on an individual as a result of a criminal conviction but not as part of the judgment of the court that imposes the conviction; or (2) that an administrative agency, official, or civil court is authorized, but not required, to impose on an individual convicted of a felony, misdemeanor, or other criminal offense. (b) Establishment (1) In general Not later than 30 days after the date of enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the Secretary Task Force (2) Membership (A) Total number of members The Task Force shall include 10 members, who shall be appointed by the Secretary in accordance with subparagraphs (B) and (C). (B) Members of the task force The Task Force shall include— (i) members who have national recognition and significant expertise in areas such as health care, housing, employment, substance use disorder, mental health, law enforcement, and law; (ii) not fewer than 2 members— (I) who have personally experienced substance abuse or addiction and are in recovery; and (II) not fewer than 1 one of whom has benefited from medication assisted treatment; and (iii) to the extent practicable, members who formerly served as elected officials at the State and Federal levels. (C) Timing The Secretary shall appoint the members of the Task Force not later than 60 days after the date on which the Task Force is established under paragraph (1). (3) Chairperson The Task Force shall select a chairperson or co-chairpersons from among the members of the Task Force. (c) Duties of the task force (1) In general The Task Force shall— (A) identify collateral consequences for individuals with Federal or State drug convictions who are in recovery for substance use disorder; and (B) determine whether the collateral consequences identified under subparagraph (A) unnecessarily delay individuals in recovery from resuming their personal and professional activities. (2) Recommendations Not later than 180 days after the date of the first meeting of the Task Force, the Task Force shall develop recommendations for proposed legislative and regulatory changes to reduce and, to the extent practicable, eliminate the collateral consequences identified by the Task Force under paragraph (1). (3) Collection of information The Task Force shall hold hearings, require the testimony and attendance of witnesses, and secure information from any department or agency of the United States in performing the duties under paragraphs (1) and (2). (4) Report Not later than 1 year after the date of the first meeting of the Task Force, the Task Force shall submit a report detailing the findings and recommendations of the Task Force to— (A) each relevant committee of Congress; (B) the head of each relevant department or agency of the United States; (C) the President; and (D) the Vice President. V Addiction and treatment services for women, families, and veterans 501. Authority to award competitive grants to address opioid and heroin abuse by pregnant and parenting female offenders Part MM of the Omnibus Crime Control and Safe Streets Act of 1968, as amended by section 302, is amended by adding at the end the following: 3038. Authority to award competitive grants to address opioid and heroin abuse by pregnant and parenting female offenders (a) Definitions In this section— (1) the term State criminal justice agency (2) the term State substance abuse agency 42 U.S.C. 300x–21 et seq. (b) Purpose and program authority (1) Grant authorization The Attorney General, in coordination with the Secretary of Health and Human Services, may award competitive grants jointly to a State substance abuse agency and a State criminal justice agency to address the use of opioids and heroin among pregnant and parenting female offenders in the State to promote public safety, public health, family permanence, and well-being. (2) Purposes and program authority A grant under this section shall be used to facilitate or enhance collaboration between the State criminal justice and State substance abuse systems in order to carry out programs to address the use of opioid and heroin abuse by pregnant and parenting female offenders. (c) Applications (1) In general A State substance abuse agency and State criminal justice agency desiring a grant under this section shall jointly submit to the Attorney General an application in such form, and containing such information, as the Attorney General may prescribe by regulation or guidelines. (2) Contents (A) In general Each application for a grant under this section shall contain a plan to expand the services of the State for pregnant and parenting female offenders for the use of opioids, heroin, and other drugs, which shall be in accordance with regulations or guidelines established by the Attorney General, in consultation with the Secretary of Health and Human Services. (B) Plan A plan submitted under subparagraph (A) shall, at a minimum, include— (i) a description of how the applicants will work jointly to address the needs associated with the use of opioids or heroin by pregnant and parenting female offenders to promote family stability and permanence; (ii) a description of the nature and the extent of the problem of opioid and heroin use by pregnant and parenting female offenders in the State; (iii) a certification that the State has involved counties and other units of local government, when appropriate, in the development, expansion, modification, operation, or improvement of proposed programs to address the problems associated with opioid and heroin use; (iv) a certification that funds received under this section will be used to supplement, not supplant, other Federal, State, and local funds; and (v) a description of clinically appropriate practices and procedures to— (I) screen and assess pregnant and parenting female offenders for problems associated with opioids and heroin; (II) screen and assess pregnant and parenting female offenders demonstrating problems associated with opioids and heroin for co-occurring mental disorders; (III) provide clinically appropriate services, including medication assisted treatment, for female offenders and their children in the same location to promote family permanence and self-sufficiency; and (IV) provide for a process to enhance or ensure the abilities of the State criminal justice agency and State substance abuse agency to work together to reunite families when appropriate in the case where family treatment is not provided. (d) Period of grant; renewal (1) Period A grant under this section shall be for a period of 3 years. (2) Renewal A State substance abuse agency and a State criminal justice agency receiving a grant under this section may apply for and, after the end of the period of the first grant under this section, receive 1 additional grant under this section. (e) Performance accountability; reports (1) Reports A State substance abuse agency and a State criminal justice agency receiving a grant under this section shall jointly submit to the Attorney General a report on the activities carried out under the grant at the end of each fiscal year during the period of the grant. (2) Evaluation Not later than 1 year after the end of the period of a grant under this section, the Attorney General shall submit a report to each committee of Congress with jurisdiction of the program under this section that summarizes the reports of the recipients of the grant and provides recommendations, if any, for further legislative action. (f) Training and technical assistance The Attorney General shall support State substance abuse and State criminal justice agencies by developing, in consultation with State substance abuse and State criminal justice agencies, and offering a program of training and technical assistance to assist the agencies in developing programs and protocols— (1) to implement this section; and (2) for effectively working across the Federal and State criminal and substance abuse systems. (g) Authorization of appropriations There are authorized to be appropriated to carry out this section $5,000,000 for each of fiscal years 2016 through 2020. . 502. Grants for family-based substance abuse treatment Section 2925 of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797s–4 (1) by striking An entity (a) Entity Reports (2) by adding at the end the following: (b) Attorney general report on family-Based substance abuse treatment The Attorney General shall submit to Congress an annual report that describes the number of grants awarded under section 2921(1) and how such grants are used by the recipients for family-based substance abuse treatment programs that serve as alternatives to incarceration for custodial parents to receive treatment and services as a family. . 503. Veterans’ treatment courts Section 2991 of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797aa (1) by redesignating subsection (i) as subsection (j); (2) by inserting after subsection (h) the following: (i) Assisting veterans (1) Definitions In this subsection: (A) Peer to peer services or programs The term peer to peer services or programs (B) Qualified veteran The term qualified veteran (i) has served on active duty in any branch of the Armed Forces, including the National Guard and reserve components; and (ii) (I) was discharged or released from such service under conditions other than dishonorable; or (II) was discharged or released from such service under dishonorable conditions, if the reason for that discharge or release, if known, is attributable to drug use. (C) Veterans treatment court program The term veterans treatment court program (i) intensive judicial supervision and case management, which may include random and frequent drug testing where appropriate; (ii) a full continuum of treatment services, including mental health services, substance abuse services, medical services, and services to address trauma; (iii) alternatives to incarceration; and (iv) other appropriate services, including housing, transportation, mentoring, employment, job training, education, and assistance in applying for and obtaining available benefits. (2) Veterans assistance program (A) In general The Attorney General, in consultation with the Secretary of Veterans Affairs, may award grants under this subsection to applicants to establish or expand— (i) veterans treatment court programs; (ii) peer to peer services or programs for qualified veterans; (iii) practices that identify and provide treatment, rehabilitation, legal, transitional, and other appropriate services to qualified veterans who have been incarcerated; and (iv) training programs to teach criminal justice, law enforcement, corrections, mental health, and substance abuse personnel how to identify and appropriately respond to incidents involving qualified veterans. (B) Priority In awarding grants under this subsection, the Attorney General shall give priority to applications that— (i) demonstrate collaboration between and joint investments by criminal justice, mental health, substance abuse, and veterans service agencies; (ii) promote effective strategies to identify and reduce the risk of harm to qualified veterans and public safety; and (iii) propose interventions with empirical support to improve outcomes for qualified veterans. ; and (3) in subsection (j), as so redesignated— (A) by redesignating paragraph (2) as paragraph (3); and (B) by inserting after paragraph (1) the following: (2) Veterans treatment courts In addition to the amounts authorized under paragraph (1), there are authorized to be appropriated to the Attorney General $5,000,000 for each of fiscal years 2016 through 2020 to carry out subsection (i). . VI Incentivizing State comprehensive initiatives to address opioid and heroin abuse 601. State demonstration grants for comprehensive opioid abuse response Part MM of the Omnibus Crime Control and Safe Streets Act of 1968, as amended by section 501, is amended by adding at the end the following: 3039. State demonstration grants for comprehensive opioid abuse response (a) Definitions In this section— (1) the term dispenser 21 U.S.C. 802 (2) the term prescriber of a schedule II, III, or IV controlled substance (A) for use on the premises on which the substance is dispensed; (B) in a hospital emergency room, when the substance is in short supply; (C) for a certified opioid treatment program; or (D) in other situations as the Attorney General may reasonably determine; (3) the term prescriber (4) the term schedule II, III, or IV controlled substance 21 U.S.C. 812(c) (b) Planning and implementation grants (1) In general The Attorney General, in coordination with the Secretary of Health and Human Services and the Director of the Office of National Drug Control Policy, may award grants to States, and combinations thereof, to prepare a comprehensive plan for and implement an integrated opioid abuse response initiative. (2) Purposes A State receiving a grant under this section shall establish a comprehensive response to opioid abuse, which shall include— (A) prevention and education efforts around heroin and opioid use, treatment, and recovery; (B) a comprehensive prescription drug monitoring program to track dispensing of schedule II, III, or IV controlled substances, which shall include— (i) data sharing with other States by statute, regulation, or interstate agreement; and (ii) educating physicians, residents, medical students, and other prescribers of Schedule II, III, or IV controlled substances on the prescription drug monitoring program of the State; (C) developing, implementing, or expanding the prescription drug and opioid addiction treatment program of the State by— (i) expanding programs for medication assisted treatment of prescription drug and opioid addiction, including training for treatment and recovery support providers; (ii) developing, implementing, or expanding programs for behavioral health therapy for individuals who are in treatment for prescription drug and opioid addiction, including contingency management, cognitive behavioral therapy, and motivational enhancements; (iii) developing, implementing, or expanding programs to screen individuals who are in treatment for prescription drug and opioid addiction for hepatitis C and HIV, and provide treatment for those individuals if clinically appropriate; or (iv) developing, implementing, or expanding programs that provide screening, early intervention, and referral to treatment (commonly referred to as SBIRT (D) developing, implementing, and expanding programs to prevent overdose death of prescription medications and opioids. (3) Planning grant applications (A) Application (i) In general A State desiring a planning grant under this section to prepare a comprehensive plan for an integrated opioid abuse response initiative shall submit to the Attorney General an application in such form, and containing such information, as the Attorney General may prescribe by regulation or guidelines. (ii) Requirements An application for a planning grant under this section shall, at a minimum, include— (I) a budget and a budget justification for the activities to be carried out using the grant; (II) a description of the activities proposed to be carried out using the grant, including a schedule for completion of such activities; (III) outcome measures that will be used to measure the effectiveness of the programs and initiatives to address opioids; and (IV) a description of the personnel necessary to complete such activities. (B) Period; nonrenewability A planning grant under this section shall be for a period of 1 year. A State may not receive more than 1 planning grant under this section. (C) Amount A planning grant under this section may not exceed $100,000, except that the Attorney General may, for good cause, approve a grant in a higher amount. (D) Strategic plan and program implementation plan A State receiving a planning grant under this section shall develop a strategic plan and a program implementation plan. (4) Implementation grants (A) Application A State desiring an implementation grant under this section to implement a comprehensive strategy for addressing opioid abuse shall submit to the Attorney General an application in such form, and containing such information, as the Attorney General may prescribe by regulation or guidelines. (B) Use of funds A State that receives an implementation grant under this section shall use the grant for the cost of carrying out an integrated opioid abuse response program in accordance with this section, including for technical assistance, training, and administrative expenses. (C) Requirements An integrated opioid abuse response program carried out using an implementation grant under this section shall— (i) ensure that each prescriber of a schedule II, III, or IV controlled substance in the State— (I) registers with the prescription drug monitoring program of the State; and (II) consults the prescription drug monitoring program database of the State before prescribing a schedule II, III, or IV controlled substance; (ii) ensure that each dispenser of a schedule II, III, or IV controlled substance in the State— (I) registers with the prescription drug monitoring program of the State; (II) consults the prescription drug monitoring program database of the State before dispensing a schedule II, III, or IV controlled substance; and (III) reports to the prescription drug monitoring program of the State, at a minimum, each instance in which a schedule II, III, or IV controlled substance is dispensed, with limited exceptions, as defined by the State, which shall indicate the prescriber by name and National Provider Identifier; (iii) require that, not fewer than 4 times each year, the State agency or agencies that administer the prescription drug monitoring program of the State prepare and provide to each prescriber of a schedule II, III, or IV controlled substance an informational report that shows how the prescribing patterns of the prescriber compare to prescribing practices of the peers of the prescriber and expected norms; (iv) if informational reports provided to a prescriber under clause (iii) indicate that the prescriber is repeatedly falling outside of expected norms or standard practices for the prescriber's field, direct the prescriber to educational resources on appropriate prescribing of controlled substances; (v) ensure that the prescriber licensing board of the State receives a report describing any prescribers that repeatedly fall outside of expected norms or standard practices for the prescriber's field, as described in clause (iii); (vi) require consultation with the Single State Authority for Substance Abuse; and (vii) establish requirements for how data will be collected and analyzed to determine the effectiveness of the program. (D) Period An implementation grant under this section shall be for a period of 2 years. (E) Amount The amount of an implementation grant under this section may not exceed $5,000,000 except that the Attorney General may, for good cause, approve a grant in a higher amount. (5) Priority considerations In awarding planning and implementation grants under this section, the Attorney General shall give priority to a State that— (A) provides civil liability protection for first responders, health professionals, and family members administering naloxone to counteract opioid overdoses by— (i) enacting legislation that provides such civil liability protection; or (ii) providing a certification by the attorney general of the State that the attorney general has— (I) reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders, health care professionals, family members, and other individuals who may administer naloxone to individuals reasonably believed to be suffering from opioid overdose; and (II) concluded that the law described in subclause (I) provides adequate civil liability protection applicable to such persons; (B) have in effect legislation or implement a policy under which the State shall not terminate, but may suspend, enrollment under the State plan for medical assistance under title XIX of the Social Security Act ( 42 U.S.C. 1396 et seq. (C) have a process for enrollment in services and benefits necessary by criminal justice agencies to initiate or continue treatment in the community, under which an individual who is incarcerated may, while incarcerated, enroll in services and benefits that are necessary for the individual to continue treatment upon release from incarceration; (D) ensures the capability of data sharing with other States, such as by making data available to a prescription monitoring hub; (E) ensures that data recorded in the prescription drug monitoring program database of the State is available within 24 hours, to the extent possible; and (F) ensures that the prescription drug monitoring program of the State notifies prescribers and dispensers of schedule II, III, or IV controlled substances when overuse or misuse of such controlled substances by patients is suspected. (c) Authorization of appropriations There are authorized to be appropriated to carry out this section $15,000,000 for each of fiscal years 2016 through 2020. . VII Offset; GAO report 701. Offset It is the sense of Congress that the amounts expended to carry out this Act and the amendments made by this Act should be offset by a corresponding reduction in Federal non-defense discretionary spending. 702. GAO report on IMD exclusion (a) Definition In this section, the term Medicaid Institutions for Mental Disease exclusion 42 U.S.C. 1396d (b) Report required Not later than 180 days after the date of enactment of this Act, the Comptroller General of the United States shall submit to Congress a report on the impact that the Medicaid Institutions for Mental Disease exclusion has on access to treatment for individuals with a substance use disorder. (c) Elements The report required under subsection (b) shall include the following: (1) An analysis of whether the following policy changes to the Medicaid Institutions for Mental Disease exclusion would enhance access to treatment for individuals with a substance use disorder: (A) Removing substance use disorder treatment and facilities from the Medicaid Institutions for Mental Disease exclusion. (B) Amending section 1905(i) of the Social Security Act ( 42 U.S.C. 1396d(i) (C) Repealing the Medicaid Institutions for Mental Disease exclusion. (2) An analysis of whether and to what extent the quality of care for substance use disorder treatment is impacted by the Medicaid Institutions for Mental Disease exclusion. (3) An analysis of barriers in accessing State-specific information related to the impact of the Medicaid Institutions for Mental Disease exclusion on access to treatment. (4) An analysis of the difference in cost between treatment for a substance use disorder in a hospital setting compared to a community-based care setting. (5) An analysis of the characteristics of institutions for mental diseases (as defined in section 1905(i) of the Social Security Act ( 42 U.S.C. 1396d(i) 1. Short title; table of contents (a) Short title This Act may be cited as the Comprehensive Addiction and Recovery Act of 2016 (b) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title; table of contents. Sec. 2. Findings. Sec. 3. Definitions. TITLE I—Prevention and education Sec. 101. Development of best practices for the use of prescription opioids. Sec. 102. Awareness campaigns. Sec. 103. Community-based coalition enhancement grants to address local drug crises. TITLE II—Law enforcement and treatment Sec. 201. Treatment alternative to incarceration programs. Sec. 202. First responder training for the use of drugs and devices that rapidly reverse the effects of opioids. Sec. 203. Prescription drug take back expansion. Sec. 204. Heroin and methamphetamine task forces. TITLE III—Treatment and recovery Sec. 301. Evidence-based opioid and heroin treatment and interventions demonstration. Sec. 302. Criminal justice medication assisted treatment and interventions demonstration. Sec. 303. National youth recovery initiative. Sec. 304. Building communities of recovery. TITLE IV—Addressing collateral consequences Sec. 401. Correctional education demonstration grant program. Sec. 402. National Task Force on Recovery and Collateral Consequences. TITLE V—Addiction and treatment services for women, families, and veterans Sec. 501. Improving treatment for pregnant and postpartum women. Sec. 502. Report on grants for family-based substance abuse treatment. Sec. 503. Veterans’ treatment courts. TITLE VI—Incentivizing State comprehensive initiatives to address opioid and heroin abuse Sec. 601. State demonstration grants for comprehensive opioid abuse response. TITLE VII—Miscellaneous Sec. 701. GAO report on IMD exclusion. Sec. 702. Funding. Sec. 703. Conforming amendments. Sec. 704. Grant accountability. 2. Findings Congress finds the following: (1) The abuse of heroin and prescription opioid painkillers is having a devastating effect on public health and safety in communities across the United States. According to the Centers for Disease Control and Prevention, drug overdose deaths now surpass traffic crashes in the number of deaths caused by injury in the United States. In 2014, an average of more than 120 people in the United States died from drug overdoses every day. (2) According to the National Institute on Drug Abuse (commonly known as NIDA (3) Opioid pain relievers are the most widely misused or abused controlled prescription drugs (commonly referred to as CPDs DAWN (4) The use of heroin in the United States has also spiked sharply in recent years. According to the most recent National Survey on Drug Use and Health, more than 900,000 people in the United States reported using heroin in 2014, nearly a 35 percent increase from the previous year. Heroin overdose deaths more than tripled from 2010 to 2014. (5) The supply of cheap heroin available in the United States has increased dramatically as well, largely due to the activity of Mexican drug trafficking organizations. The Drug Enforcement Administration (commonly known as the DEA (6) Law enforcement officials and treatment experts throughout the country report that many prescription opioid users have turned to heroin as a cheaper or more easily obtained alternative to prescription drugs. (7) According to a report by the National Association of State Alcohol and Drug Abuse Directors (commonly referred to as NASADAD (8) Research indicates that combating the opioid crisis, including abuse of prescription painkillers and, increasingly, heroin, requires a multi-pronged approach that involves prevention, education, monitoring, law enforcement initiatives, reducing drug diversion and the supply of illicit drugs, expanding delivery of existing treatments (including medication assisted treatments), expanding access to overdose medications and interventions, and the development of new medications for pain that can augment the existing treatment arsenal. (9) Substance use disorders are a treatable disease. Discoveries in the science of addiction have led to advances in the treatment of substance use disorders that help people stop abusing drugs and prescription medications and resume their productive lives. (10) According to the National Survey on Drug Use and Health, approximately 22,700,000 people in the United States needed substance use disorder treatment in 2013, but only 2,500,000 people received it. Furthermore, current treatment services are not adequate to meet demand. According to a report commissioned by the Substance Abuse and Mental Health Services Administration (commonly known as SAMHSA (11) The overall cost of drug abuse, from health care- and criminal justice-related costs to lost productivity, is steep, totaling more than $700,000,000,000 a year, according to NIDA. Effective substance abuse prevention can yield major economic dividends. (12) According to NIDA, when schools and communities properly implement science-validated substance abuse prevention programs, abuse of alcohol, tobacco, and illicit drugs is reduced. Such programs help teachers, parents, and healthcare professionals shape the perceptions of youths about the risks of drug abuse. (13) Diverting certain individuals with substance use disorders from criminal justice systems into community-based treatment can save billions of dollars and prevent sizeable numbers of crimes, arrests, and re-incarcerations over the course of those individuals’ lives. (14) According to the DEA, more than 2,700 tons of expired, unwanted prescription medications have been collected since the enactment of the Secure and Responsible Drug Disposal Act of 2010 ( Public Law 111–273 (15) Faith-based, holistic, or drug-free models can provide a critical path to successful recovery for a great number of people in the United States. The 2015 membership survey conducted by Alcoholics Anonymous (commonly known as AA (16) Research shows that combining treatment medications with behavioral therapy is an effective way to facilitate success for some patients. Treatment approaches must be tailored to address the drug abuse patterns and drug-related medical, psychiatric, and social problems of each individual. Different types of medications may be useful at different stages of treatment or recovery to help a patient stop using drugs, stay in treatment, and avoid relapse. Patients have a range of options regarding their path to recovery and many have also successfully addressed drug abuse through the use of faith-based, holistic, or drug-free models. (17) Individuals with mental illness, especially severe mental illness, are at considerably higher risk for substance abuse than the general population, and the presence of a mental illness complicates recovery from substance abuse. 3. Definitions In this Act— (1) the term medication assisted treatment (2) the term opioid (3) the term State I Prevention and education 101. Development of best practices for the use of prescription opioids (a) Definitions In this section— (1) the term Secretary (2) the term task force (b) Inter-Agency Task Force Not later than December 14, 2018, the Secretary, in cooperation with the Secretary of Veterans Affairs, the Secretary of Defense, and the Administrator of the Drug Enforcement Administration, shall convene a Pain Management Best Practices Inter-Agency Task Force to review, modify, and update, as appropriate, best practices for pain management (including chronic and acute pain) and prescribing pain medication. (c) Membership The task force shall be comprised of— (1) representatives of— (A) the Department of Health and Human Services; (B) the Department of Veterans Affairs; (C) the Food and Drug Administration; (D) the Department of Defense; (E) the Drug Enforcement Administration; (F) the Centers for Disease Control and Prevention; (G) the National Academy of Medicine; (H) the National Institutes of Health; and (I) the Office of National Drug Control Policy; (2) physicians, dentists, and non-physician prescribers; (3) pharmacists; (4) experts in the fields of pain research and addiction research; (5) representatives of— (A) pain management professional organizations; (B) the mental health treatment community; (C) the addiction treatment community; (D) pain advocacy groups; and (E) groups with expertise around overdose reversal; and (6) other stakeholders, as the Secretary determines appropriate. (d) Duties The task force shall— (1) not later than 180 days after the date on which the task force is convened under subsection (b), review, modify, and update, as appropriate, best practices for pain management (including chronic and acute pain) and prescribing pain medication, taking into consideration— (A) existing pain management research; (B) recommendations from relevant conferences; (C) ongoing efforts at the State and local levels and by medical professional organizations to develop improved pain management strategies, including consideration of alternatives to opioids to reduce opioid monotherapy in appropriate cases; (D) the management of high-risk populations, other than populations who suffer pain, who— (i) may use or be prescribed benzodiazepines, alcohol, and diverted opioids; or (ii) receive opioids in the course of medical care; and (E) the Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain issued by the Centers for Disease Control and Prevention (80 Fed. Reg. 77351 (December 14, 2015)) and any final guidelines issued by the Centers for Disease Control and Prevention; (2) solicit and take into consideration public comment on the practices developed under paragraph (1), amending such best practices if appropriate; and (3) develop a strategy for disseminating information about the best practices to stakeholders, as appropriate. (e) Limitation The task force shall not have rulemaking authority. (f) Report Not later than 270 days after the date on which the task force is convened under subsection (b), the task force shall submit to Congress a report that includes— (1) the strategy for disseminating best practices for pain management (including chronic and acute pain) and prescribing pain medication, as reviewed, modified, or updated under subsection (d); (2) the results of a feasibility study on linking the best practices described in paragraph (1) to receiving and renewing registrations under section 303(f) of the Controlled Substances Act ( 21 U.S.C. 823(f) (3) recommendations for effectively applying the best practices described in paragraph (1) to improve prescribing practices at medical facilities, including medical facilities of the Veterans Health Administration. 102. Awareness campaigns (a) In general The Secretary of Health and Human Services, in coordination with the Attorney General, shall advance the education and awareness of the public, providers, patients, and other appropriate entities regarding the risk of abuse of prescription opioid drugs if such products are not taken as prescribed. (b) Drug-Free Media Campaign (1) In general The Office of National Drug Control Policy, in coordination with the Secretary of Health and Human Services and the Attorney General, shall establish a national drug awareness campaign. (2) Requirements The national drug awareness campaign required under paragraph (1) shall— (A) take into account the association between prescription opioid abuse and heroin use; (B) emphasize the similarities between heroin and prescription opioids and the effects of heroin and prescription opioids on the human body; and (C) bring greater public awareness to the dangerous effects of fentanyl when mixed with heroin or abused in a similar manner. 103. Community-based coalition enhancement grants to address local drug crises Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2997. Community-based coalition enhancement grants to address local drug crises (a) Definitions In this section— (1) the term Drug-Free Communities Act of 1997 21 U.S.C. 1521 et seq. (2) the term eligible entity (A) on or before the date of submitting an application for a grant under this section, receives or has received a grant under the Drug-Free Communities Act of 1997; and (B) has documented, using local data, rates of abuse of opioids or methamphetamines at levels that are— (i) significantly higher than the national average as determined by the Attorney General (including appropriate consideration of the results of the Monitoring the Future Survey published by the National Institute on Drug Abuse and the National Survey on Drug Use and Health published by the Substance Abuse and Mental Health Services Administration); or (ii) higher than the national average, as determined by the Attorney General (including appropriate consideration of the results of the surveys described in clause (i)), over a sustained period of time; and (3) the term local drug crisis (A) a sudden increase in the abuse of opioids or methamphetamines, as documented by local data; or (B) the abuse of prescription medications, specifically opioids or methamphetamines, that is significantly higher than the national average, over a sustained period of time, as documented by local data. (b) Program authorized The Attorney General, in coordination with the Director of the Office of National Drug Control Policy, may make grants to eligible entities to implement comprehensive community-wide strategies that address local drug crises within the area served by the eligible entity. (c) Application (1) In general An eligible entity seeking a grant under this section shall submit an application to the Attorney General at such time, in such manner, and accompanied by such information as the Attorney General may require. (2) Criteria As part of an application for a grant under this section, the Attorney General shall require an eligible entity to submit a detailed, comprehensive, multi-sector plan for addressing the local drug crisis within the area served by the eligible entity. (d) Use of funds An eligible entity shall use a grant received under this section— (1) for programs designed to implement comprehensive community-wide prevention strategies to address the local drug crisis in the area served by the eligible entity, in accordance with the plan submitted under subsection (c)(2); and (2) to obtain specialized training and technical assistance from the organization funded under section 4 of Public Law 107–82 21 U.S.C. 1521 (e) Supplement not supplant An eligible entity shall use Federal funds received under this section only to supplement the funds that would, in the absence of those Federal funds, be made available from other Federal and non-Federal sources for the activities described in this section, and not to supplant those funds. (f) Evaluation A grant under this section shall be subject to the same evaluation requirements and procedures as the evaluation requirements and procedures imposed on the recipient of a grant under the Drug-Free Communities Act of 1997. (g) Limitation on administrative expenses Not more than 8 percent of the amounts made available pursuant to subsection (i) for a fiscal year may be used by the Attorney General to pay for administrative expenses. . II Law enforcement and treatment 201. Treatment alternative to incarceration programs (a) Definitions In this section: (1) Eligible entity The term eligible entity (2) Eligible participant The term eligible participant (A) comes into contact with the juvenile justice system or criminal justice system or is arrested or charged with an offense that is not— (i) a crime of violence, as defined under applicable State law or section 16 of title 18, United States Code; or (ii) a serious drug offense, as defined under section 924(e)(2)(A) of title 18, United States Code; (B) has a current— (i) substance use disorder; or (ii) co-occurring mental illness and substance use disorder; and (C) has been approved for participation in a program funded under this section by, as applicable depending on the stage of the criminal justice process, the relevant law enforcement agency or prosecuting attorney, defense attorney, probation or corrections official, judge, or representative from the relevant mental health or substance abuse agency. (b) Program authorized The Secretary of Health and Human Services, in coordination with the Attorney General, may make grants to eligible entities to— (1) develop, implement, or expand a treatment alternative to incarceration program for eligible participants, including— (A) pre-booking, including pre-arrest, treatment alternative to incarceration programs, including— (i) law enforcement training on substance use disorders and co-occurring mental illness and substance use disorders; (ii) receiving centers as alternatives to incarceration of eligible participants; (iii) specialized response units for calls related to substance use disorders and co-occurring mental illness and substance use disorders; and (iv) other pre-arrest or pre-booking treatment alternative to incarceration models; and (B) post-booking treatment alternative to incarceration programs, including— (i) specialized clinical case management; (ii) pre-trial services related to substance use disorders and co-occurring mental illness and substance use disorders; (iii) prosecutor and defender based programs; (iv) specialized probation; (v) programs utilizing the American Society of Addiction Medicine patient placement criteria; (vi) treatment and rehabilitation programs and recovery support services; and (vii) drug courts, DWI courts, and veterans treatment courts; and (2) facilitate or enhance planning and collaboration between State criminal justice systems and State substance abuse systems in order to more efficiently and effectively carry out programs described in paragraph (1) that address problems related to the use of heroin and misuse of prescription drugs among eligible participants. (c) Application (1) In general An eligible entity desiring a grant under this section shall submit an application to the Secretary of Health and Human Services— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Secretary of Health and Human Services may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) provide extensive evidence of collaboration with State and local government agencies overseeing health, community corrections, courts, prosecution, substance abuse, mental health, victims services, and employment services, and with local law enforcement agencies; (B) demonstrate consultation with the Single State Authority for Substance Abuse; (C) demonstrate consultation with the Single State criminal justice planning agency; (D) demonstrate that evidence-based treatment practices, including if applicable the use of medication assisted treatment, will be utilized; and (E) demonstrate that evidenced-based screening and assessment tools will be utilized to place participants in the treatment alternative to incarceration program. (d) Requirements Each eligible entity awarded a grant for a treatment alternative to incarceration program under this section shall— (1) determine the terms and conditions of participation in the program by eligible participants, taking into consideration the collateral consequences of an arrest, prosecution, or criminal conviction; (2) ensure that each substance abuse and mental health treatment component is licensed and qualified by the relevant jurisdiction; (3) for programs described in subsection (b)(2), organize an enforcement unit comprised of appropriately trained law enforcement professionals under the supervision of the State, tribal, or local criminal justice agency involved, the duties of which shall include— (A) the verification of addresses and other contacts of each eligible participant who participates or desires to participate in the program; and (B) if necessary, the location, apprehension, arrest, and return to court of an eligible participant in the program who has absconded from the facility of a treatment provider or has otherwise violated the terms and conditions of the program, consistent with Federal and State confidentiality requirements; (4) notify the relevant criminal justice entity if any eligible participant in the program absconds from the facility of the treatment provider or otherwise violates the terms and conditions of the program, consistent with Federal and State confidentiality requirements; (5) submit periodic reports on the progress of treatment or other measured outcomes from participation in the program of each eligible participant in the program to the relevant State, tribal, or local criminal justice agency; (6) describe the evidence-based methodology and outcome measurements that will be used to evaluate the program, and specifically explain how such measurements will provide valid measures of the impact of the program; and (7) describe how the program could be broadly replicated if demonstrated to be effective. (e) Use of funds An eligible entity shall use a grant received under this section for expenses of a treatment alternative to incarceration program, including— (1) salaries, personnel costs, equipment costs, and other costs directly related to the operation of the program, including the enforcement unit; (2) payments for treatment providers that are approved by the relevant State or tribal jurisdiction and licensed, if necessary, to provide needed treatment to eligible participants in the program, including medication assisted treatment, aftercare supervision, vocational training, education, and job placement; (3) payments to public and nonprofit private entities that are approved by the State or tribal jurisdiction and licensed, if necessary, to provide alcohol and drug addiction treatment and mental health treatment to eligible participants in the program; and (4) salaries, personnel costs, and other costs related to strategic planning among State and local government agencies. (f) Supplement not supplant An eligible entity shall use Federal funds received under this section only to supplement the funds that would, in the absence of those Federal funds, be made available from other Federal and non-Federal sources for the activities described in this section, and not to supplant those funds. (g) Geographic distribution The Secretary of Health and Human Services shall ensure that, to the extent practicable, the geographical distribution of grants under this section is equitable and includes a grant to an eligible entity in— (1) each State; (2) rural, suburban, and urban areas; and (3) tribal jurisdictions. (h) Priority consideration with respect to States In awarding grants to States under this section, the Secretary of Health and Human Services shall give priority to— (1) a State that submits a joint application from the substance abuse agencies and criminal justice agencies of the State that proposes to use grant funds to facilitate or enhance planning and collaboration between the agencies, including coordination to better address the needs of incarcerated populations; and (2) a State that— (A) provides civil liability protection for first responders, health professionals, and family members who have received appropriate training in the administration of naloxone in administering naloxone to counteract opioid overdoses; and (B) submits to the Secretary a certification by the attorney general of the State that the attorney general has— (i) reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders, health care professionals, family members, and other individuals who— (I) have received appropriate training in the administration of naloxone; and (II) may administer naloxone to individuals reasonably believed to be suffering from opioid overdose; and (ii) concluded that the law described in subparagraph (A) provides adequate civil liability protection applicable to such persons. (i) Reports and evaluations (1) In general Each fiscal year, each recipient of a grant under this section during that fiscal year shall submit to the Secretary of Health and Human Services a report on the outcomes of activities carried out using that grant in such form, containing such information, and on such dates as the Secretary of Health and Human Services shall specify. (2) Contents A report submitted under paragraph (1) shall— (A) describe best practices for treatment alternatives; and (B) identify training requirements for law enforcement officers who participate in treatment alternative to incarceration programs. (j) Funding During the 5-year period beginning on the date of enactment of this Act, the Secretary of Health and Human Services shall carry out this section using funds made available to the Substance Abuse and Mental Health Services Administration for Criminal Justice Activities. 202. First responder training for the use of drugs and devices that rapidly reverse the effects of opioids Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2998. First responder training for the use of drugs and devices that rapidly reverse the effects of opioids (a) Definition In this section— (1) the terms drug device 21 U.S.C. 321 (2) the term eligible entity (3) the term first responder (4) the term Secretary (b) Program authorized The Secretary, in coordination with the Attorney General, may make grants to eligible entities to allow appropriately trained first responders to administer an opioid overdose reversal drug to an individual who has— (1) experienced a prescription opioid or heroin overdose; or (2) been determined to have likely experienced a prescription opioid or heroin overdose. (c) Application (1) In general An eligible entity seeking a grant under this section shall submit an application to the Secretary— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Secretary may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) describe the evidence-based methodology and outcome measurements that will be used to evaluate the program funded with a grant under this section, and specifically explain how such measurements will provide valid measures of the impact of the program; (B) describe how the program could be broadly replicated if demonstrated to be effective; (C) identify the governmental and community agencies that the program will coordinate; and (D) describe how law enforcement agencies will coordinate with their corresponding State substance abuse and mental health agencies to identify protocols and resources that are available to victims and families, including information on treatment and recovery resources. (d) Use of funds An eligible entity shall use a grant received under this section to— (1) make such opioid overdose reversal drugs or devices that are approved by the Food and Drug Administration, such as naloxone, available to be carried and administered by first responders; (2) train and provide resources for first responders on carrying an opioid overdose reversal drug or device approved by the Food and Drug Administration, such as naloxone, and administering the drug or device to an individual who has experienced, or has been determined to have likely experienced, a prescription opioid or heroin overdose; and (3) establish processes, protocols, and mechanisms for referral to appropriate treatment. (e) Technical assistance grants The Secretary shall make a grant for the purpose of providing technical assistance and training on the use of an opioid overdose reversal drug, such as naloxone, to respond to an individual who has experienced, or has been determined to have likely experienced, a prescription opioid or heroin overdose, and mechanisms for referral to appropriate treatment for an eligible entity receiving a grant under this section. (f) Evaluation The Secretary shall conduct an evaluation of grants made under this section to determine— (1) the number of first responders equipped with naloxone, or another opioid overdose reversal drug, for the prevention of fatal opioid and heroin overdose; (2) the number of opioid and heroin overdoses reversed by first responders receiving training and supplies of naloxone, or another opioid overdose reversal drug, through a grant received under this section; (3) the number of calls for service related to opioid and heroin overdose; (4) the extent to which overdose victims and families receive information about treatment services and available data describing treatment admissions; and (5) the research, training, and naloxone, or another opioid overdose reversal drug, supply needs of first responder agencies, including those agencies that are not receiving grants under this section. (g) Rural areas with limited access to emergency medical services In making grants under this section, the Secretary shall ensure that not less than 25 percent of grant funds are awarded to eligible entities that are not located in metropolitan statistical areas, as defined by the Office of Management and Budget. . 203. Prescription drug take back expansion (a) Definition of covered entity In this section, the term covered entity (1) a State, local, or tribal law enforcement agency; (2) a manufacturer, distributor, or reverse distributor of prescription medications; (3) a retail pharmacy; (4) a registered narcotic treatment program; (5) a hospital or clinic with an on-site pharmacy; (6) an eligible long-term care facility; or (7) any other entity authorized by the Drug Enforcement Administration to dispose of prescription medications. (b) Program authorized The Attorney General, in coordination with the Administrator of the Drug Enforcement Administration, the Secretary of Health and Human Services, and the Director of the Office of National Drug Control Policy, shall coordinate with covered entities in expanding or making available disposal sites for unwanted prescription medications. 204. Heroin and methamphetamine task forces Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999. Heroin and methamphetamine task forces The Attorney General may make grants to State law enforcement agencies for investigative purposes— (1) to locate or investigate illicit activities through statewide collaboration, including activities related to— (A) the distribution of heroin or fentanyl, or the unlawful distribution of prescription opioids; or (B) unlawful heroin, fentanyl, and prescription opioid traffickers; and (2) to locate or investigate illicit activities, including precursor diversion, laboratories, or methamphetamine traffickers. . III Treatment and recovery 301. Evidence-based opioid and heroin treatment and interventions demonstration Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999A. Evidence-based opioid and heroin treatment and interventions demonstration (a) Definitions In this section— (1) the terms Indian tribe tribal organization 25 U.S.C. 1603 (2) the term medication assisted treatment (3) the term Secretary (4) the term State substance abuse agency 42 U.S.C. 300x–21 et seq. (b) Grants (1) Authority to make grants The Secretary, acting through the Director of the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration, and in coordination with the Attorney General and other departments or agencies, as appropriate, may award grants to State substance abuse agencies, units of local government, nonprofit organizations, and Indian tribes or tribal organizations that have a high rate, or have had a rapid increase, in the use of heroin or other opioids, in order to permit such entities to expand activities, including an expansion in the availability of medication assisted treatment and other clinically appropriate services, with respect to the treatment of addiction in the specific geographical areas of such entities where there is a high rate or rapid increase in the use of heroin or other opioids. (2) Nature of activities The grant funds awarded under paragraph (1) shall be used for activities that are based on reliable scientific evidence of efficacy in the treatment of problems related to heroin or other opioids. (c) Geographic distribution The Secretary shall ensure that grants awarded under subsection (b) are distributed equitably among the various regions of the United States and among rural, urban, and suburban areas that are affected by the use of heroin or other opioids. (d) Additional activities In administering grants under subsection (b), the Secretary shall— (1) evaluate the activities supported by grants awarded under subsection (b); (2) disseminate information, as appropriate, derived from the evaluation as the Secretary considers appropriate; (3) provide States, Indian tribes and tribal organizations, and providers with technical assistance in connection with the provision of treatment of problems related to heroin and other opioids; and (4) fund only those applications that specifically support recovery services as a critical component of the grant program. . 302. Criminal justice medication assisted treatment and interventions demonstration (a) Definitions In this section— (1) the term criminal justice agency (A) court; (B) prison; (C) jail; or (D) other agency that performs the administration of criminal justice, including prosecution, pretrial services, and community supervision; (2) the term eligible entity (3) the term Secretary (b) Program authorized The Secretary, in coordination with the Attorney General, may make grants to eligible entities to implement medication assisted treatment programs through criminal justice agencies. (c) Application (1) In general An eligible entity seeking a grant under this section shall submit an application to the Secretary— (A) that meets the criteria under paragraph (2); and (B) at such time, in such manner, and accompanied by such information as the Secretary may require. (2) Criteria An eligible entity, in submitting an application under paragraph (1), shall— (A) certify that each medication assisted treatment program funded with a grant under this section has been developed in consultation with the Single State Authority for Substance Abuse; and (B) describe how data will be collected and analyzed to determine the effectiveness of the program described in subparagraph (A). (d) Use of funds An eligible entity shall use a grant received under this section for expenses of— (1) a medication assisted treatment program, including the expenses of prescribing medications recognized by the Food and Drug Administration for opioid treatment in conjunction with psychological and behavioral therapy; (2) training criminal justice agency personnel and treatment providers on medication assisted treatment; (3) cross-training personnel providing behavioral health and health services, administration of medicines, and other administrative expenses, including required reports; and (4) the provision of recovery coaches who are responsible for providing mentorship and transition plans to individuals reentering society following incarceration or alternatives to incarceration. (e) Priority consideration with respect to States In awarding grants to States under this section, the Secretary shall give priority to a State that— (1) provides civil liability protection for first responders, health professionals, and family members who have received appropriate training in the administration of naloxone in administering naloxone to counteract opioid overdoses; and (2) submits to the Secretary a certification by the attorney general of the State that the attorney general has— (A) reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders, health care professionals, family members, and other individuals who— (i) have received appropriate training in the administration of naloxone; and (ii) may administer naloxone to individuals reasonably believed to be suffering from opioid overdose; and (B) concluded that the law described in subparagraph (A) provides adequate civil liability protection applicable to such persons. (f) Technical assistance The Secretary, in coordination with the Director of the National Institute on Drug Abuse and the Attorney General, shall provide technical assistance and training for an eligible entity receiving a grant under this section. (g) Reports (1) In general An eligible entity receiving a grant under this section shall submit a report to the Secretary on the outcomes of each grant received under this section for individuals receiving medication assisted treatment, based on— (A) the recidivism of the individuals; (B) the treatment outcomes of the individuals, including maintaining abstinence from illegal, unauthorized, and unprescribed or undispensed opioids and heroin; (C) a comparison of the cost of providing medication assisted treatment to the cost of incarceration or other participation in the criminal justice system; (D) the housing status of the individuals; and (E) the employment status of the individuals. (2) Contents and timing Each report described in paragraph (1) shall be submitted annually in such form, containing such information, and on such dates as the Secretary shall specify. (h) Funding During the 5-year period beginning on the date of enactment of this Act, the Secretary shall carry out this section using funds made available to the Substance Abuse and Mental Health Services Administration for Criminal Justice Activities. 303. National youth recovery initiative Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999B. National youth recovery initiative (a) Definitions In this section: (1) Eligible entity The term eligible entity (A) a high school that has been accredited as a recovery high school by the Association of Recovery Schools; (B) an accredited high school that is seeking to establish or expand recovery support services; (C) an institution of higher education; (D) a recovery program at a nonprofit collegiate institution; or (E) a nonprofit organization. (2) Institution of higher education The term institution of higher education 20 U.S.C. 1001 (3) Recovery program The term recovery program (A) means a program to help individuals who are recovering from substance use disorders to initiate, stabilize, and maintain healthy and productive lives in the community; and (B) includes peer-to-peer support and communal activities to build recovery skills and supportive social networks. (b) Grants authorized The Secretary of Health and Human Services, in coordination with the Secretary of Education, may award grants to eligible entities to enable the entities to— (1) provide substance use recovery support services to young people in high school and enrolled in institutions of higher education; (2) help build communities of support for young people in recovery through a spectrum of activities such as counseling and health- and wellness-oriented social activities; and (3) encourage initiatives designed to help young people achieve and sustain recovery from substance use disorders. (c) Use of funds Grants awarded under subsection (b) may be used for activities to develop, support, and maintain youth recovery support services, including— (1) the development and maintenance of a dedicated physical space for recovery programs; (2) dedicated staff for the provision of recovery programs; (3) health- and wellness-oriented social activities and community engagement; (4) establishment of recovery high schools; (5) coordination of recovery programs with— (A) substance use disorder treatment programs and systems; (B) providers of mental health services; (C) primary care providers and physicians; (D) the criminal justice system, including the juvenile justice system; (E) employers; (F) housing services; (G) child welfare services; (H) high schools and institutions of higher education; and (I) other programs or services related to the welfare of an individual in recovery from a substance use disorder; (6) the development of peer-to-peer support programs or services; and (7) additional activities that help youths and young adults to achieve recovery from substance use disorders. . 304. Building communities of recovery Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999C. Building communities of recovery (a) Definition In this section, the term recovery community organization (1) mobilizes resources within and outside of the recovery community to increase the prevalence and quality of long-term recovery from substance use disorders; and (2) is wholly or principally governed by people in recovery for substance use disorders who reflect the community served. (b) Grants authorized The Secretary of Health and Human Services may award grants to recovery community organizations to enable such organizations to develop, expand, and enhance recovery services. (c) Federal share The Federal share of the costs of a program funded by a grant under this section may not exceed 50 percent. (d) Use of funds Grants awarded under subsection (b)— (1) shall be used to develop, expand, and enhance community and statewide recovery support services; and (2) may be used to— (A) advocate for individuals in recovery from substance use disorders; (B) build connections between recovery networks, between recovery community organizations, and with other recovery support services, including— (i) substance use disorder treatment programs and systems; (ii) providers of mental health services; (iii) primary care providers and physicians; (iv) the criminal justice system; (v) employers; (vi) housing services; (vii) child welfare agencies; and (viii) other recovery support services that facilitate recovery from substance use disorders; (C) reduce the stigma associated with substance use disorders; (D) conduct public education and outreach on issues relating to substance use disorders and recovery, including— (i) how to identify the signs of addiction; (ii) the resources that are available to individuals struggling with addiction and families who have a family member struggling with or being treated for addiction, including programs that mentor and provide support services to children; (iii) the resources that are available to help support individuals in recovery; and (iv) information on the medical consequences of substance use disorders, including neonatal abstinence syndrome and potential infection with human immunodeficiency virus and viral hepatitis; and (E) carry out other activities that strengthen the network of community support for individuals in recovery. . IV Addressing collateral consequences 401. Correctional education demonstration grant program Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999D. Correctional education demonstration grant program (a) Definition In this section, the term eligible entity (b) Grant program authorized The Attorney General may make grants to eligible entities to design, implement, and expand educational programs for offenders in prisons, jails, and juvenile facilities, including to pay for— (1) basic education, secondary level academic education, high school equivalency examination preparation, career technical education, and English as a second language instruction at the basic, secondary, or post-secondary levels, for adult and juvenile populations; (2) screening and assessment of inmates to assess education level, needs, occupational interest or aptitude, risk level, and other needs, and case management services; (3) hiring and training of instructors and aides, reimbursement of non-corrections staff and experts, reimbursement of stipends paid to inmate tutors or aides, and the costs of training inmate tutors and aides; (4) instructional supplies and equipment, including occupational program supplies and equipment to the extent that the supplies and equipment are used for instructional purposes; (5) partnerships and agreements with community colleges, universities, and career technology education program providers; (6) certification programs providing recognized high school equivalency certificates and industry recognized credentials; and (7) technology solutions to— (A) meet the instructional, assessment, and information needs of correctional populations; and (B) facilitate the continued participation of incarcerated students in community-based education programs after the students are released from incarceration. (c) Application An eligible entity seeking a grant under this section shall submit to the Attorney General an application in such form and manner, at such time, and accompanied by such information as the Attorney General specifies. (d) Priority considerations In awarding grants under this section, the Attorney General shall give priority to applicants that— (1) assess the level of risk and need of inmates, including by— (A) assessing the need for English as a second language instruction; (B) conducting educational assessments; and (C) assessing occupational interests and aptitudes; (2) target educational services to assessed needs, including academic and occupational at the basic, secondary, or post-secondary level; (3) target career technology education programs to— (A) areas of identified occupational demand; and (B) employment opportunities in the communities in which students are reasonably expected to reside post-release; (4) include a range of appropriate educational opportunities at the basic, secondary, and post-secondary levels; (5) include opportunities for students to attain industry recognized credentials; (6) include partnership or articulation agreements linking institutional education programs with community sited programs provided by adult education program providers and accredited institutions of higher education, community colleges, and vocational training institutions; and (7) explicitly include career pathways models offering opportunities for incarcerated students to develop academic skills, in-demand occupational skills and credentials, occupational experience in institutional work programs or work release programs, and linkages with employers in the community, so that incarcerated students have opportunities to embark on careers with strong prospects for both post-release employment and advancement in a career ladder over time. (e) Requirements An eligible entity desiring a grant under this section shall— (1) describe the evidence-based methodology and outcome measurements that will be used to evaluate each program funded with a grant under this section, and specifically explain how such measurements will provide valid measures of the impact of the program; and (2) describe how the program described in paragraph (1) could be broadly replicated if demonstrated to be effective. (f) Control of Internet access An entity that receives a grant under this section may restrict access to the Internet by prisoners, as appropriate and in accordance with Federal and State law, to ensure public safety. . 402. National Task Force on Recovery and Collateral Consequences (a) Definition In this section, the term collateral consequence (b) Establishment (1) In general Not later than 30 days after the date of enactment of this Act, the Attorney General shall establish a bipartisan task force to be known as the Task Force on Recovery and Collateral Consequences (in this section referred to as the Task Force (2) Membership (A) Total number of members The Task Force shall include 10 members, who shall be appointed by the Attorney General in accordance with subparagraphs (B) and (C). (B) Members of the task force The Task Force shall include— (i) members who have national recognition and significant expertise in areas such as health care, housing, employment, substance use disorders, mental health, law enforcement, and law; (ii) not fewer than 2 members— (I) who have personally experienced substance abuse or addiction and are in recovery; and (II) not fewer than 1 one of whom has benefitted from medication assisted treatment; and (iii) to the extent practicable, members who formerly served as elected officials at the State and Federal levels. (C) Timing The Attorney General shall appoint the members of the Task Force not later than 60 days after the date on which the Task Force is established under paragraph (1). (3) Chairperson The Task Force shall select a chairperson or co-chairpersons from among the members of the Task Force. (c) Duties of the task force (1) In general The Task Force shall— (A) identify collateral consequences for individuals with Federal or State convictions for drug-related offenses who are in recovery for substance use disorder; and (B) examine any policy basis for the imposition of collateral consequences identified under subparagraph (A) and the effect of the collateral consequences on individuals in recovery from resuming their personal and professional activities. (2) Recommendations Not later than 180 days after the date of the first meeting of the Task Force, the Task Force shall develop recommendations, as it considers appropriate, for proposed legislative and regulatory changes related to the collateral consequences identified under paragraph (1). (3) Collection of information The Task Force shall hold hearings, require the testimony and attendance of witnesses, and secure information from any department or agency of the United States in performing the duties under paragraphs (1) and (2). (4) Report (A) Submission to executive branch Not later than 1 year after the date of the first meeting of the Task Force, the Task Force shall submit a report detailing the findings and recommendations of the Task Force to— (i) the head of each relevant department or agency of the United States; (ii) the President; and (iii) the Vice President. (B) Submission to Congress The individuals who receive the report under subparagraph (A) shall submit to Congress such legislative recommendations, if any, as those individuals consider appropriate based on the report. V Addiction and treatment services for women, families, and veterans 501. Improving treatment for pregnant and postpartum women Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999E. Improving treatment for pregnant and postpartum women (a) In general The Secretary of Health and Human Services (referred to in this section as the Secretary (1) enhance flexibility in the use of funds designed to support family-based services for pregnant and postpartum women with a primary diagnosis of a substance use disorder, including opioid use disorders; (2) help State substance abuse agencies address identified gaps in services furnished to such women along the continuum of care, including services provided to women in non-residential based settings; and (3) promote a coordinated, effective, and efficient State system managed by State substance abuse agencies by encouraging new approaches and models of service delivery that are evidence-based, including effective family-based programs for women involved with the criminal justice system. (b) Requirements In carrying out the pilot program under this section, the Secretary— (1) shall require State substance abuse agencies to submit to the Secretary applications, in such form and manner and containing such information as specified by the Secretary, to be eligible to receive a grant under the program; (2) shall identify, based on such submitted applications, State substance abuse agencies that are eligible for such grants; (3) shall require services proposed to be furnished through such a grant to support family-based treatment and other services for pregnant and postpartum women with a primary diagnosis of a substance use disorder, including opioid use disorders; (4) shall not require that services furnished through such a grant be provided solely to women that reside in facilities; and (5) shall not require that grant recipients under the program make available all services described in section 508(d) of the Public Health Service Act ( 42 U.S.C. 290bb–1(d) (c) Required services (1) In general The Secretary shall specify minimum services required to be made available to eligible women through a grant awarded under the pilot program under this section. Such minimum services— (A) shall include the requirements described in section 508(c) of the Public Health Service Act ( 42 U.S.C. 290bb–1(c) (B) may include any of the services described in section 508(d) of the Public Health Service Act ( 42 U.S.C. 290bb–1(d) (C) may include other services, as appropriate; and (D) shall be based on the recommendations submitted under paragraph (2). (2) Stakeholder input The Secretary shall convene and solicit recommendations from stakeholders, including State substance abuse agencies, health care providers, persons in recovery from a substance use disorder, and other appropriate individuals, for the minimum services described in paragraph (1). (d) Duration The pilot program under this section shall not exceed 5 years. (e) Evaluation and report to Congress (1) In general Out of amounts made available to the Center for Behavioral Health Statistics and Quality, the Director of the Center for Behavioral Health Statistics and Quality, in cooperation with the recipients of grants under this section, shall conduct an evaluation of the pilot program, beginning 1 year after the date on which a grant is first awarded under this section. The Director of the Center for Behavioral Health Statistics and Quality, in coordination with the Director of the Center for Substance Abuse Treatment, not later than 120 days after completion of such evaluation, shall submit to the relevant Committees of the Senate and the House of Representatives a report on such evaluation. (2) Contents The report to Congress under paragraph (1) shall include, at a minimum, outcomes information from the pilot program, including any resulting reductions in the use of alcohol and other drugs, engagement in treatment services, retention in the appropriate level and duration of services, increased access to the use of drugs approved by the Food and Drug Administration for the treatment of substance use disorders in combination with counseling, and other appropriate measures. (f) State substance abuse agency defined For purposes of this section, the term State substance abuse agency . 502. Report on grants for family-based substance abuse treatment Section 2925 of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797s–4 (1) by striking An entity (a) Entity Reports (2) by adding at the end the following: (b) Attorney general report on family-Based substance abuse treatment The Attorney General shall submit to Congress an annual report that describes the number of grants awarded under section 2921(1) and how such grants are used by the recipients for family-based substance abuse treatment programs that serve as alternatives to incarceration for custodial parents to receive treatment and services as a family. . 503. Veterans’ treatment courts Section 2991(j)(1)(B)(ii) of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797aa(j)(1)(B)(ii) (1) by inserting (I) (ii) (2) in subclause (I), as so designated, by striking the period and inserting ; or (3) by adding at the end the following: (II) was discharged or released from such service under dishonorable conditions, if the reason for that discharge or release, if known, is attributable to drug use. . VI Incentivizing State comprehensive initiatives to address opioid and heroin abuse 601. State demonstration grants for comprehensive opioid abuse response (a) Definitions In this section— (1) the term dispenser 21 U.S.C. 802 (2) the term prescriber of a schedule II, III, or IV controlled substance (A) for use on the premises on which the substance is dispensed; (B) in a hospital emergency room, when the substance is in short supply; (C) for a certified opioid treatment program; or (D) in other situations as the Attorney General may reasonably determine; (3) the term prescriber (4) the term schedule II, III, or IV controlled substance 21 U.S.C. 812(c) (b) Planning and implementation grants (1) In general The Attorney General, in coordination with the Secretary of Health and Human Services and in consultation with the Director of the Office of National Drug Control Policy, may award grants to States, and combinations thereof, to prepare a comprehensive plan for and implement an integrated opioid abuse response initiative. (2) Purposes A State receiving a grant under this section shall establish a comprehensive response to opioid abuse, which shall include— (A) prevention and education efforts around heroin and opioid use, treatment, and recovery, including education of residents, medical students, and physicians and other prescribers of schedule II, III, or IV controlled substances on relevant prescribing guidelines and the prescription drug monitoring program of the State ; (B) a comprehensive prescription drug monitoring program to track dispensing of schedule II, III, or IV controlled substances, which shall— (i) provide for data sharing with other States by statute, regulation, or interstate agreement; and (ii) allow for access to all individuals authorized by the State to write prescriptions for schedule II, III, or IV controlled substances on the prescription drug monitoring program of the State. (C) developing, implementing, or expanding prescription drug and opioid addiction treatment programs by— (i) expanding programs for medication assisted treatment of prescription drug and opioid addiction, including training for treatment and recovery support providers; (ii) developing, implementing, or expanding programs for behavioral health therapy for individuals who are in treatment for prescription drug and opioid addiction; (iii) developing, implementing, or expanding programs to screen individuals who are in treatment for prescription drug and opioid addiction for hepatitis C and HIV, and provide treatment for those individuals if clinically appropriate; or (iv) developing, implementing, or expanding programs that provide screening, early intervention, and referral to treatment (commonly known as SBIRT (D) developing, implementing, and expanding programs to prevent overdose death from prescription medications and opioids. (3) Planning grant applications (A) Application (i) In general A State seeking a planning grant under this section to prepare a comprehensive plan for an integrated opioid abuse response initiative shall submit to the Attorney General an application in such form, and containing such information, as the Attorney General may require. (ii) Requirements An application for a planning grant under this section shall, at a minimum, include— (I) a budget and a budget justification for the activities to be carried out using the grant; (II) a description of the activities proposed to be carried out using the grant, including a schedule for completion of such activities; (III) outcome measures that will be used to measure the effectiveness of the programs and initiatives to address opioids; and (IV) a description of the personnel necessary to complete such activities. (B) Period; nonrenewability A planning grant under this section shall be for a period of 1 year. A State may not receive more than 1 planning grant under this section. (C) Amount A planning grant under this section may not exceed $100,000. (D) Strategic plan and program implementation plan A State receiving a planning grant under this section shall develop a strategic plan and a program implementation plan. (4) Implementation grants (A) Application A State seeking an implementation grant under this section to implement a comprehensive strategy for addressing opioid abuse shall submit to the Attorney General an application in such form, and containing such information, as the Attorney General may require. (B) Use of funds A State that receives an implementation grant under this section shall use the grant for the cost of carrying out an integrated opioid abuse response program in accordance with this section, including for technical assistance, training, and administrative expenses. (C) Requirements An integrated opioid abuse response program carried out using an implementation grant under this section shall— (i) require that each prescriber of a schedule II, III, or IV controlled substance in the State— (I) registers with the prescription drug monitoring program of the State; and (II) consults the prescription drug monitoring program database of the State before prescribing a schedule II, III, or IV controlled substance; (ii) require that each dispenser of a schedule II, III, or IV controlled substance in the State— (I) registers with the prescription drug monitoring program of the State; (II) consults the prescription drug monitoring program database of the State before dispensing a schedule II, III, or IV controlled substance; and (III) reports to the prescription drug monitoring program of the State, at a minimum, each instance in which a schedule II, III, or IV controlled substance is dispensed, with limited exceptions, as defined by the State, which shall indicate the prescriber by name and National Provider Identifier; (iii) require that, not fewer than 4 times each year, the State agency or agencies that administer the prescription drug monitoring program of the State prepare and provide to each prescriber of a schedule II, III, or IV controlled substance an informational report that shows how the prescribing patterns of the prescriber compare to prescribing practices of the peers of the prescriber and expected norms; (iv) if informational reports provided to a prescriber under clause (iii) indicate that the prescriber is repeatedly falling outside of expected norms or standard practices for the prescriber's field, direct the prescriber to educational resources on appropriate prescribing of controlled substances; (v) ensure that the prescriber licensing board of the State receives a report describing any prescribers that repeatedly fall outside of expected norms or standard practices for the prescriber's field, as described in clause (iii); (vi) require consultation with the Single State Authority for Substance Abuse; and (vii) establish requirements for how data will be collected and analyzed to determine the effectiveness of the program. (D) Period An implementation grant under this section shall be for a period of 2 years. (E) Amount The amount of an implementation grant under this section may not exceed $5,000,000. (5) Priority considerations In awarding planning and implementation grants under this section, the Attorney General shall give priority to a State that— (A) (i) provides civil liability protection for first responders, health professionals, and family members who have received appropriate training in the administration of naloxone in administering naloxone to counteract opioid overdoses; and (ii) submits to the Attorney General a certification by the attorney general of the State that the attorney general has— (I) reviewed any applicable civil liability protection law to determine the applicability of the law with respect to first responders, health care professionals, family members, and other individuals who— (aa) have received appropriate training in the administration of naloxone; and (bb) may administer naloxone to individuals reasonably believed to be suffering from opioid overdose; and (II) concluded that the law described in subclause (I) provides adequate civil liability protection applicable to such persons; (B) has in effect legislation or implements a policy under which the State shall not terminate, but may suspend, enrollment under the State plan for medical assistance under title XIX of the Social Security Act ( 42 U.S.C. 1396 et seq. (C) has a process for enrollment in services and benefits necessary by criminal justice agencies to initiate or continue treatment in the community, under which an individual who is incarcerated may, while incarcerated, enroll in services and benefits that are necessary for the individual to continue treatment upon release from incarceration; (D) ensures the capability of data sharing with other States, such as by making data available to a prescription monitoring hub; (E) ensures that data recorded in the prescription drug monitoring program database of the State is available within 24 hours, to the extent possible; and (F) ensures that the prescription drug monitoring program of the State notifies prescribers and dispensers of schedule II, III, or IV controlled substances when overuse or misuse of such controlled substances by patients is suspected. (c) Authorization of Funding For each of fiscal years 2016 through 2020, the Attorney General may use, from any unobligated balances made available under the heading GENERAL ADMINISTRATION VII Miscellaneous 701. GAO report on IMD exclusion (a) Definition In this section, the term Medicaid Institutions for Mental Disease exclusion 42 U.S.C. 1396d (b) Report required Not later than 1 year after the date of enactment of this Act, the Comptroller General of the United States shall submit to Congress a report on the impact that the Medicaid Institutions for Mental Disease exclusion has on access to treatment for individuals with a substance use disorder. (c) Elements The report required under subsection (b) shall include a review of what is known regarding— (1) Medicaid beneficiary access to substance use disorder treatments in institutions for mental disease; and (2) the quality of care provided to Medicaid beneficiaries treated in and outside of institutions for mental disease for substance use disorders. 702. Funding Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999F. Funding There are authorized to be appropriated to the Attorney General and the Secretary of Health and Human Services to carry out this part $77,900,000 for each of fiscal years 2016 through 2020. . 703. Conforming amendments Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. (1) in the part heading, by striking CONFRONTING USE OF METHAMPHETAMINE COMPREHENSIVE ADDICTION AND RECOVERY (2) in section 2996(a)(1), by striking this part this section 704. Grant accountability (a) Grants under part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 Part II of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797cc et seq. 2999G. Grant accountability (a) Definitions In this section— (1) the term applicable committees (A) with respect to the Attorney General and any other official of the Department of Justice, means— (i) the Committee on the Judiciary of the Senate; and (ii) the Committee on the Judiciary of the House of Representatives; and (B) with respect to the Secretary of Health and Human Services and any other official of the Department of Health and Human Services, means— (i) the Committee on Health, Education, Labor, and Pensions of the Senate; and (ii) the Committee on Energy and Commerce of the House of Representatives; (2) the term covered agency (A) the Department of Justice; and (B) the Department of Health and Human Services; and (3) the term covered official (A) the Attorney General; and (B) the Secretary of Health and Human Services. (b) Accountability All grants awarded by a covered official under this part shall be subject to the following accountability provisions: (1) Audit requirement (A) Definition In this paragraph, the term unresolved audit finding (B) Audit Beginning in the first fiscal year beginning after the date of enactment of this section, and in each fiscal year thereafter, the Inspector General of a covered agency shall conduct audits of recipients of grants awarded by the applicable covered official under this part to prevent waste, fraud, and abuse of funds by grantees. The Inspector General shall determine the appropriate number of grantees to be audited each year. (C) Mandatory exclusion A recipient of grant funds under this part that is found to have an unresolved audit finding shall not be eligible to receive grant funds under this part during the first 2 fiscal years beginning after the end of the 12-month period described in subparagraph (A). (D) Priority In awarding grants under this part, a covered official shall give priority to eligible applicants that did not have an unresolved audit finding during the 3 fiscal years before submitting an application for a grant under this part. (E) Reimbursement If an entity is awarded grant funds under this part during the 2-fiscal-year period during which the entity is barred from receiving grants under subparagraph (C), the covered official that awarded the grant funds shall— (i) deposit an amount equal to the amount of the grant funds that were improperly awarded to the grantee into the General Fund of the Treasury; and (ii) seek to recoup the costs of the repayment to the fund from the grant recipient that was erroneously awarded grant funds. (2) Nonprofit organization requirements (A) Definition For purposes of this paragraph and the grant programs under this part, the term nonprofit organization section 501(c)(3) (B) Prohibition A covered official may not award a grant under this part to a nonprofit organization that holds money in offshore accounts for the purpose of avoiding paying the tax described in section 511(a) (C) Disclosure Each nonprofit organization that is awarded a grant under this part and uses the procedures prescribed in regulations to create a rebuttable presumption of reasonableness for the compensation of its officers, directors, trustees, and key employees, shall disclose to the applicable covered official, in the application for the grant, the process for determining such compensation, including the independent persons involved in reviewing and approving such compensation, the comparability data used, and contemporaneous substantiation of the deliberation and decision. Upon request, a covered official shall make the information disclosed under this subparagraph available for public inspection. (3) Conference expenditures (A) Limitation No amounts made available to a covered official under this part may be used by the covered official, or by any individual or entity awarded discretionary funds through a cooperative agreement under this part, to host or support any expenditure for conferences that uses more than $20,000 in funds made available by the covered official, unless the covered official provides prior written authorization that the funds may be expended to host the conference. (B) Written authorization Written authorization under subparagraph (A) shall include a written estimate of all costs associated with the conference, including the cost of all food, beverages, audio-visual equipment, honoraria for speakers, and entertainment. (C) Report (i) Department of Justice The Deputy Attorney General shall submit to the applicable committees an annual report on all conference expenditures approved by the Attorney General under this paragraph. (ii) Department of Health and Human Services The Deputy Secretary of Health and Human Services shall submit to the applicable committees an annual report on all conference expenditures approved by the Secretary of Health and Human Services under this paragraph. (4) Annual certification Beginning in the first fiscal year beginning after the date of enactment of this section, each covered official shall submit to the applicable committees an annual certification— (A) indicating whether— (i) all audits issued by the Office of the Inspector General of the applicable agency under paragraph (1) have been completed and reviewed by the appropriate Assistant Attorney General or Director, or the appropriate official of the Department of Health and Human Services, as applicable; (ii) all mandatory exclusions required under paragraph (1)(C) have been issued; and (iii) all reimbursements required under paragraph (1)(E) have been made; and (B) that includes a list of any grant recipients excluded under paragraph (1) from the previous year. (c) Preventing duplicative grants (1) In general Before a covered official awards a grant to an applicant under this part, the covered official shall compare potential grant awards with other grants awarded under this part by the covered official to determine if duplicate grant awards are awarded for the same purpose. (2) Report If a covered official awards duplicate grants to the same applicant for the same purpose, the covered official shall submit to the applicable committees a report that includes— (A) a list of all duplicate grants awarded, including the total dollar amount of any duplicate grants awarded; and (B) the reason the covered official awarded the duplicate grants. . (b) Other grants (1) Definitions In this subsection— (A) the term applicable committees (i) with respect to the Attorney General and any other official of the Department of Justice, means— (I) the Committee on the Judiciary of the Senate; and (II) the Committee on the Judiciary of the House of Representatives; and (ii) with respect to the Secretary of Health and Human Services and any other official of the Department of Health and Human Services, means— (I) the Committee on Health, Education, Labor, and Pensions of the Senate; and (II) the Committee on Energy and Commerce of the House of Representatives; (B) the term covered agency (i) the Department of Justice; and (ii) the Department of Health and Human Services; and (C) the term covered official (i) the Attorney General; and (ii) the Secretary of Health and Human Services. (2) Accountability All grants awarded by a covered official under section 201, 302, or 601 shall be subject to the following accountability provisions: (A) Audit requirement (i) Definition In this subparagraph, the term unresolved audit finding (ii) Audit Beginning in the first fiscal year beginning after the date of enactment of this Act, and in each fiscal year thereafter, the Inspector General of a covered agency shall conduct audits of recipients of grants awarded by the applicable covered official under section 201, 302, or 601 to prevent waste, fraud, and abuse of funds by grantees. The Inspector General shall determine the appropriate number of grantees to be audited each year. (iii) Mandatory exclusion A recipient of grant funds under section 201, 302, or 601 that is found to have an unresolved audit finding shall not be eligible to receive grant funds under those sections during the first 2 fiscal years beginning after the end of the 12-month period described in clause (i). (iv) Priority In awarding grants under section 201, 302, or 601, a covered official shall give priority to eligible applicants that did not have an unresolved audit finding during the 3 fiscal years before submitting an application for a grant under such section. (v) Reimbursement If an entity is awarded grant funds under section 201, 302, or 601 during the 2-fiscal-year period during which the entity is barred from receiving grants under clause (iii), the covered official that awarded the funds shall— (I) deposit an amount equal to the amount of the grant funds that were improperly awarded to the grantee into the General Fund of the Treasury; and (II) seek to recoup the costs of the repayment to the fund from the grant recipient that was erroneously awarded grant funds. (B) Nonprofit organization requirements (i) Definition For purposes of this subparagraph and the grant programs under sections 201, 302, and 601, the term nonprofit organization section 501(c)(3) (ii) Prohibition A covered official may not award a grant under this section 201, 302, or 601 to a nonprofit organization that holds money in offshore accounts for the purpose of avoiding paying the tax described in section 511(a) (iii) Disclosure Each nonprofit organization that is awarded a grant under section 201, 302, or 601 and uses the procedures prescribed in regulations to create a rebuttable presumption of reasonableness for the compensation of its officers, directors, trustees, and key employees, shall disclose to the applicable covered official, in the application for the grant, the process for determining such compensation, including the independent persons involved in reviewing and approving such compensation, the comparability data used, and contemporaneous substantiation of the deliberation and decision. Upon request, a covered official shall make the information disclosed under this clause available for public inspection. (C) Conference expenditures (i) Limitation No amounts made available to a covered official under section 201, 302, or 601 may be used by the covered official, or by any individual or entity awarded discretionary funds through a cooperative agreement under those sections, to host or support any expenditure for conferences that uses more than $20,000 in funds made available by the covered official, unless the covered official provides prior written authorization that the funds may be expended to host the conference. (ii) Written authorization Written authorization under clause (i) shall include a written estimate of all costs associated with the conference, including the cost of all food, beverages, audio-visual equipment, honoraria for speakers, and entertainment. (iii) Report (I) Department of Justice The Deputy Attorney General shall submit to the applicable committees an annual report on all conference expenditures approved by the Attorney General under this subparagraph. (II) Department of Health and Human Services The Deputy Secretary of Health and Human Services shall submit to the applicable committees an annual report on all conference expenditures approved by the Secretary of Health and Human Services under this subparagraph. (D) Annual certification Beginning in the first fiscal year beginning after the date of enactment of this Act, each covered official shall submit to the applicable committees an annual certification— (i) indicating whether— (I) all audits issued by the Office of the Inspector General of the applicable agency under subparagraph (A) have been completed and reviewed by the appropriate Assistant Attorney General or Director, or the appropriate official of the Department of Health and Human Services, as applicable; (II) all mandatory exclusions required under subparagraph (A)(iii) have been issued; and (III) all reimbursements required under subparagraph (A)(v) have been made; and (ii) that includes a list of any grant recipients excluded under subparagraph (A) from the previous year. (3) Preventing duplicative grants (A) In general Before a covered official awards a grant to an applicant under section 201, 302, or 601, the covered official shall compare potential grant awards with other grants awarded under those sections by the covered official to determine if duplicate grant awards are awarded for the same purpose. (B) Report If a covered official awards duplicate grants to the same applicant for the same purpose, the covered official shall submit to the to the applicable committees a report that includes— (i) a list of all duplicate grants awarded, including the total dollar amount of any duplicate grants awarded; and (ii) the reason the covered official awarded the duplicate grants. February 22, 2016 Reported with an amendment

Summary: (This measure has not been amended since the Conference Report was filed in the House on July 6, 2016. The summary of that version is repeated here.) Comprehensive Addiction and Recovery Act of 2016 TITLE I--PREVENTION AND EDUCATION (Sec. 101) This bill requires the Department of Health and Human Services (HHS) to convene a Pain Management Best Practices Inter-Agency Task Force to review best practices for pain management developed or adopted by federal agencies. The task force must propose updates to best practices and recommendations for addressing gaps or inconsistencies. (Sec. 102) HHS must advance education and awareness regarding the risk of abuse of prescription opioids if they are not taken as prescribed. (Opioids are drugs with effects similar to opium, such as certain pain medications and heroin.) (Sec. 103) The Office of National Drug Control Policy, in coordination with the Substance Abuse and Mental Health Services Administration, may award grants to implement community-wide strategies to address a high rate of, or sudden increase in, opioid or methamphetamine abuse or a sudden increase in opioid-related deaths. (Sec. 104) HHS must report on the availability of information regarding the prescription of opioids after youth sports injury, including information on opioid use and misuse, injury treatments that do not involve opioids, and treatment for opioid addiction. The report must determine the extent this information is available to teenagers and adolescents who play youth sports, their families, youth sports groups, and health care providers. Taking into consideration the findings of the report, HHS may facilitate the development of such information. (Sec. 105) This bill amends the Public Health Service Act to require HHS to award grants to states to: (1) streamline state requirements and procedures to assist certain veterans to meet state certification, licensure, and other requirements applicable to civilian health care professions; and (2) develop or expand career pathways at institutions of higher education to support veterans in meeting such requirements. (Sec. 106) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to refer new drug applications for opioids to an advisory committee before approval, unless the FDA finds that such a referral is scientifically unnecessary and not in the interest of protecting and promoting public health and the FDA notifies Congress of its rationale. The FDA must convene an advisory committee on labeling opioids for pediatric use before approving any such labeling. As part of its evaluation of the Extended-Release/Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, the FDA must develop recommendations regarding education programs for prescribers of opioids. The FDA must finalize the draft guidance entitled "General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products." (Sec. 107) HHS must award grants to expand access to drugs or devices approved by the FDA for emergency treatment of opioid overdose (e.g., naloxone). Grant recipients may use the funds to purchase such treatments, establish a program for prescribing such treatments, train health care providers and pharmacists, offset patient cost sharing, and connect patients to treatment. HHS may provide information to prescribers in federally qualified health centers and Indian Health Service facilities on best practices for prescribing such treatments. The Department of Defense and the Department of Veterans Affairs may provide such information to prescribers in their medical facilities. (Sec. 108) The National Institutes of Health (NIH) may intensify and coordinate NIH research into the understanding of pain, therapies for chronic pain, and alternatives to opioids for pain treatments. The prioritization and direction of federally funded pain research must consider recommendations made by the Interagency Pain Research Coordinating Committee. (Sec. 109) The grant program for state prescription drug monitoring programs is extended through FY2021 and revised, including to: allow grants to be used to maintain and operate existing state prescription drug monitoring programs, require HHS to redistribute any returned funds among the remaining grantees, require a state to provide HHS with aggregate data to enable HHS to evaluate the success of the state's program, and expand the program to include any commonwealth or territory of the United States. The Drug Enforcement Administration (DEA), HHS, a state Medicaid program, a state health department, or a state substance abuse agency receiving nonidentifiable information from a prescription drug monitoring database for research purposes may make that information available to other entities for research purposes. A state receiving a grant must: (1) facilitate prescriber and dispenser use of the state's prescription drug monitoring system, and (2) educate prescribers and dispensers on the benefits of the system both to them and society. (Sec. 110) HHS must make grants to states that allow standing orders (documents that allow a person to acquire, dispense, or administer a prescription medication without a person-specific prescription) for drugs or devices for emergency treatment of opioid overdose (e.g., naloxone). Grants may be used for: implementing strategies for pharmacists to dispense such treatments pursuant to a standing order, encouraging pharmacies to dispense such treatments pursuant to a standing order, developing or providing training materials for prescribers to use in educating the public on administration of such treatments, and educating the public on the availability of such treatments. States must report on pharmacies that dispense such treatments under a standing order. TITLE II--LAW ENFORCEMENT AND TREATMENT (Sec. 201) This bill amends the Omnibus Crime Control and Safe Streets Act of 1968 to authorize the Department of Justice (DOJ) to award grants to state, local, and tribal governments to provide opioid abuse services, including: developing, implementing, or expanding a treatment alternative to incarceration program; enhancing collaboration between criminal justice and substance abuse agencies; developing, implementing, or expanding programs to prevent, treat, or respond to opioid abuse; training first responders to administer opioid overdose treatments; and investigating unlawful opioid distribution activities. This bill amends the Justice Assistance Act of 1984 to eliminate existing authority for DOJ to award grants under the Emergency Federal Law Enforcement Assistance Program through FY2021. The Family-Based Substance Abuse Treatment Program is expanded to include prison-based family treatment programs for pregnant women. The Government Accountability Office (GAO) must report on how federal grant programs address substance use and substance use disorders among adolescents and young adults. (Sec. 202) HHS must make grants to states, local governmental entities, Indian tribes, and tribal organizations to enable first responders and others to administer drugs or devices for emergency treatment of opioid overdose. Grants may be used to make such treatments available, train first responders and others on the use of such treatments, and establish processes to refer individuals receiving treatment to follow-up care. (Sec. 203) DOJ must coordinate with law enforcement agencies, pharmacies, distributors of prescription medications, and others to expand or make available disposal sites for unwanted prescription medications. TITLE III--TREATMENT AND RECOVERY (Sec. 301) HHS must provide support to state substance abuse agencies, units of local government, nonprofit organizations, and Indian tribes and tribal organizations that have a high rate of, or a rapid increase in, use of opioids to expand treatment of addiction in the areas affected. (Sec. 302) HHS must award grants to enable recovery community organizations to develop, expand, and enhance substance use disorder recovery services. A recovery community organization is a nonprofit organization governed by people in recovery for substance use disorders that mobilizes resources to increase the prevalence and quality of long-term recovery. (Sec. 303) This bill amends the Controlled Substances Act to revise the qualifications required for a practitioner to administer, dispense, or prescribe narcotic drugs for maintenance or detoxification treatment in an office-based opioid treatment program. The bill expands qualifying practitioners to include licensed nurse practitioners and physician assistants who have expertise and prescribe medications for opioid use disorder in collaboration with or under the supervision of a qualifying physician if state law requires physician oversight of prescribing authority. Qualifying practitioners must comply with reporting requirements and have the capacity to provide all FDA-approved drugs for opioid use disorder and other ancillary services. HHS may change the maximum patient limit for qualifying practitioners. HHS must update the treatment improvement protocol containing best practice guidelines for the treatment of opioid-dependent patients in office-based settings. TITLE IV--ADDRESSING COLLATERAL CONSEQUENCES (Sec. 401) The GAO must report on the collateral consequences for individuals with convictions for nonviolent drug-related offenses, including the effect of those consequences on individuals resuming their personal and professional activities and the justifications for imposing those consequences. Collateral consequences are penalties or disadvantages imposed on such individuals by law, an administrative agency, or a court, not including consequences imposed at sentencing. TITLE V--ADDICTION AND TREATMENT SERVICES FOR WOMEN, FAMILIES, AND VETERANS (Sec. 501) Support for residential substance abuse treatment programs for pregnant and postpartum women is expanded to include outpatient treatment and extended through FY2021. Such programs must provide services to the children of participants, including therapeutic, comprehensive child care. Priority for support must be given to programs serving rural areas, health professional shortage areas, or areas with a shortage of family-based substance use disorder treatment options. The Center for Substance Abuse Treatment must carry out a pilot program to make grants to state substance abuse agencies to support services for pregnant and postpartum women who have a primary diagnosis of a substance use disorder, including opioid use disorders. The Center for Behavioral Health Statistics and Quality must evaluate the pilot program. (Sec. 502) DOJ may award grants to state, local, and tribal governments to establish or expand programs for veterans, including veterans treatment courts, peer-to-peer services, and treatment, rehabilitation, legal, or transitional services for incarcerated veterans. (Sec. 503) This bill amends the Child Abuse Prevention and Treatment Act to require the national clearinghouse for information relating to child abuse to maintain and disseminate information about requirements and best practices relating to the development of plans of safe care for infants born affected by substance abuse symptoms, withdrawal symptoms, or a Fetal Alcohol Spectrum Disorder. The plan of safe care for such infants that is required for a state to receive a grant to improve its child protective services system must: (1) address the health and substance use disorder treatment needs of the infant and affected family or caregiver, and (2) specify a system for monitoring whether and in what manner local entities are providing services in accordance with state requirements. Annual state data reports must include the number of such infants, the number for whom a plan of safe care was developed, and the number for whom referrals are made for services, including services for the affected family or caregiver. HHS must monitor state compliance with child protective services system grant requirements. (Sec. 504) The GAO must report on: the prevalence of neonatal abstinence syndrome (NAS), which is the symptoms of withdrawal in a newborn; NAS treatment services for which coverage is available under state Medicaid programs; the care settings and reimbursement for NAS treatment; the prevalence of use of various care settings for NAS treatment under state Medicaid programs; any federal barriers to treating infants with NAS under state Medicaid programs; what is known about best practices for treating infants with NAS; and its recommendations for improvements that will ensure access to NAS treatment under state Medicaid programs. TITLE VI--INCENTIVIZING STATE COMPREHENSIVE INITIATIVES TO ADDRESS PRESCRIPTION OPIOID ABUSE (Sec. 601) HHS must award grants to establish and implement a comprehensive state and local response to opioid abuse that includes education efforts, a prescription drug monitoring program, prescription drug and opioid addiction treatment programs, and overdose death prevention efforts. HHS must give priority to entities that: (1) provide civil liability protection for first responders, health professionals, or family members who are trained in administering an opioid overdose treatment; (2) enroll incarcerated drug offenders in community-based treatment services prior to reentry; (3) ensure that data from their prescription drug monitoring program can be shared with other states and is regularly updated; and (4) maximize use of prescription drug monitoring programs and ensure programs notify prescribers and dispensers of suspected abuse of controlled substances by patients. TITLE VII--MISCELLANEOUS (Sec. 701) Each fiscal year, DOJ's Office of the Inspector General must audit a number of opioid abuse services grant recipients. Grant recipients with unresolved audit findings are not eligible to receive grant funds for two years. Nonprofit organizations that hold money in offshore accounts to avoid tax liability may not receive grant funds. DOJ and HHS must each enter into an arrangement with the National Academy of Sciences or a nonfederal entity to evaluate the effectiveness of grants pertaining to opioid abuse established by this bill. The bill limits expenditures for conferences under these grants. (Sec. 702) This bill amends the Controlled Substances Act to allow a pharmacist to partially fill a prescription for a schedule II controlled substance (such as an opioid) if: (1) such partial fills are not prohibited by state law, (2) a partial fill is requested by the patient or prescribing practitioner, and (3) the total quantity dispensed in partial fillings does not exceed the quantity prescribed. (Sec. 703) The GAO must report on the Office of National Drug Control Policy's review of state and local Good Samaritan laws that exempt from criminal or civil liability any individual who administers an opioid overdose reversal drug or device (e.g., naloxone) or who contacts emergency services providers in response to an overdose. (Sec. 704) This bill amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act (SSAct) to authorize prescription drug plan (PDP) sponsors to establish a drug management program for beneficiaries at-risk for prescription drug abuse. PDP sponsors with drug management programs must provide to the Centers for Medicare and Medicaid Services (CMS) data on limitations imposed on beneficiaries and data to identify patterns of drug use that may indicate fraudulent, medically unnecessary, or unsafe use. PDP sponsors must have in place a utilization management tool designed to prevent the abuse and diversion of frequently abused drugs. Medicare drug integrity contractors (MEDICs) may accept an individual's prescription and necessary medical records from pharmacies, PDPs, and physicians in order to provide information relevant to determining whether the individual is an at-risk beneficiary. The Inspector General of HHS must study the effectiveness of MEDICs in identifying, combating, and preventing Medicare fraud. Funds are made available to the Medicare Improvement Fund for services provided during and after FY2021. (Sec. 705) This bill amends title XIX (Medicaid) of the SSAct to exclude abuse-deterrent prescription drugs from the requirement that manufacturers of single-source or innovator drugs pay additional rebates to state Medicaid programs. (Sec. 706) Under current law, the CMS must use analytic technologies to identify improper Medicaid claims. The bill prohibits a state agency from using or disclosing such technologies except for purposes of administering a state Medicaid program or Children's Health Insurance Program (CHIP). State agencies must have adequate data security and control policies to ensure that access to such information is restricted to authorized persons for authorized uses. (Sec. 707) The bill places $5 million in the Medicaid Improvement Fund to be available beginning in FY2021. TITLE VIII--KINGPIN DESIGNATION IMPROVEMENT (Sec. 801) This bill amends the Foreign Narcotics Kingpin Designation Act to allow classified information to be submitted to a reviewing court ex parte (without all parties present) or in camera (in private) in a judicial review of a determination by the President that a foreign person is subject to sanctions as a significant foreign narcotics trafficker. TITLE IX--DEPARTMENT OF VETERANS AFFAIRS Jason Simcakoski Memorial and Promise Act Subtitle A--Opioid Therapy and Pain Management (Sec. 911) This bill directs the Department of Veterans Affairs (VA) to expand its Opioid Safety Initiative to include all VA medical facilities. The VA must direct its health care providers, before initiating opioid therapy, to use the VA's Opioid Therapy Risk Report tool, which must include: (1) information from state prescription drug monitoring programs, (2) a patient's most recent information, and (3) information on controlled substances prescribed to a patient outside the VA. The VA must establish enhanced standards for urine drug tests before and during opioid therapy to help prevent substance abuse, dependence, and diversion. The VA must use the Interdisciplinary Chronic Pain Management Training Team Program to provide education and training on pain management and safe opioid prescribing practices. Each VA medical facility must designate a pain management team of health care professionals to coordinate pain management therapy for patients experiencing pain that is not related to cancer. VA health care providers to must provide information on prescriptions of controlled substances received by veterans to state prescription drug monitoring programs. The VA must: (1) maximize the availability to veterans of opioid overdose reversal drugs, such as naloxone; (2) equip each VA pharmacy with such medications for outpatient use; and (3) expand the Overdose Education and Naloxone Distribution program to ensure that veterans receiving VA health care who are at risk of opioid overdose may access such drugs and training on the proper administration of such drugs. The VA must modify its patient record system to ensure that health care providers who access a veteran's record will be immediately notified about whether the veteran is receiving opioid therapy, has a history of substance use disorder or overdose, or is at risk of developing an opioid use disorder. (Sec. 912) The VA and the Department of Defense (DOD) must ensure that the VA/DOD Pain Management Working Group: (1) includes a focus on specified practices, (2) coordinates with other working groups, (3) consults with other federal agencies, and (4) and consults with the VA and DOD regarding proposed updates to the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. The VA and DOD must update the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. (Sec. 913) The GAO must report on the VA's Opioid Safety Initiative and the opioid prescribing practices of VA health care providers. The VA must report on opioid therapy and prescription rates for VA patients and notify Congress and investigate if a provider's or facility's prescription rate is inconsistent with safe care standards. (Sec. 914) The bill makes mandatory the disclosure by the VA of certain information to a state prescription drug monitoring program in order to prevent misuse of prescription medicines by a veteran or dependent. (Sec. 915) Veterans at high risk of an opioid overdose are exempt from paying a copayment to the VA for opioid overdose treatments. Veterans are exempt from paying a copayment to the VA for education on the use of such treatments. Subtitle B--Patient Advocacy (Sec. 921) At least once every 90 days, each VA medical facility must host a public meeting on improving health care furnished by the VA. Community-based VA outpatient clinics must host such meetings at least once every year. (Sec. 922) Not more than 90 days after enactment of this bill, the VA must display: (1) the purposes of the Patient Advocacy Program and patient advocate contact information at VA medical facilities, and (2) the rights and responsibilities of patients and family members at medical and residential facilities. (Sec. 923) The GAO must report on the Patient Advocacy Program and include an assessment of staffing, staff training, and awareness and use of the program. (Sec. 924) The Office of Patient Advocacy is established in the VA's Office of the Under Secretary for Health. The office must carry out the Patient Advocacy Program and ensure that patient advocates are trained and advocate on behalf of veterans receiving or seeking health care through the VA. Subtitle C--Complementary and Integrative Health (Sec. 931) The bill establishes the Creating Options for Veterans' Expedited Recovery Commission or the COVER Commission to examine the evidence-based therapy treatment model used by the VA for treating mental health conditions of veterans and the potential benefits of incorporating complementary and integrative treatments including music, acupuncture, yoga, meditation, and sports. Not more than 90 days after receiving a report from the commission with recommendations, the VA must submit a report that includes: (1) an action plan for implementing recommendations and a time frame for implementing complementary and integrative treatments, and (2) a justification for any determination that a recommendation is not appropriate or feasible and an alternative solution to improve the therapy model. (Sec. 932) The VA must develop a plan to expand the scope of its research and education on, and delivery and integration of, complementary and integrative health services. (Sec. 933) The VA must carry out a pilot program to assess the feasibility and advisability of using complementary and integrative health and wellness-based services by complementing the provision of pain management and related health care services with such services. In selecting the medical centers for this pilot program, the VA must give priority to centers where the prescription rate of opioids conflicts or is inconsistent with the standards of appropriate and safe care. Subtitle D--Fitness of Health Care Providers (Sec. 941) As part of the VA's hiring process for health care providers, the VA must require from each medical board that licensed the provider information on any violation of the license and any settlement agreement for a disciplinary charge relating to the provider's practice of medicine. (Sec. 942) The VA must provide information on any violation of a medical license by a VA health care provider to each medical board licensing that provider. (Sec. 943) Not later than 180 days after enactment of this bill, the VA must report on its compliance with its policy to review each health care provider who transfers, resigns, retires, or is terminated to determine whether there are any concerns, complaints, or allegations of violations relating to the medical practice of the provider and take appropriate action. Subtitle E--Other Matters (Sec. 951) This bill amends the Veterans Access, Choice, and Accountability Act of 2014 to reduce the aggregate amount of awards and bonuses that may be paid by the VA in each of FY2017-FY2021.